

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057361
Article Type:	Original research
Date Submitted by the Author:	07-Oct-2021
Complete List of Authors:	Nwogu-Onyemkpa, Eberechi; Baylor College of Medicine, Department of Medicine, Center of Excellence in Health Equity, Training and Research; Baylor College of Medicine, Section of Geriatrics and Palliative Medicine Dongarwar, Deepa; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Salihu, HM; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Akpati, Lois; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Marroquin, Maricarmen; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Abadom, Megan; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Naik, AD; Baylor College of Medicine, Section of Geriatrics and Palliative Medicine; Michael E DeBakey VA Medical Center, Houston Center for Innovations in Quality, Effectiveness, and Safety
Keywords:	Adult palliative care < PALLIATIVE CARE, HAEMATOLOGY, Anaemia < HAEMATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Title: Inpatient palliative care use by patients with sickle cell disease: a**
4 **retrospective cross-sectional study**
5
6

7 **Eberechi Nwogu-Onyemkpa, MD^{1,2}, Deepa Dongarwar, MS¹, Hamisu M. Salihu, MD,**
8 **PhD¹, Lois Akpati, BS¹, Maricarmen Marroquin, BS¹, Megan Abadom, BS¹, Aanand D.**
9 **Naik, MD^{2,3}**
10

11 **Affiliations:** ¹Baylor College of Medicine Center of Excellence in Health Equity, Training and
12 Research
13

14 ²Department of Medicine, Section of Geriatrics and Palliative Medicine, Baylor College of
15 Medicine
16

17 ³Houston Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA
18 Medical Center, Houston, Texas
19
20
21
22

23 Word count: 2,952
24
25
26

27 **Corresponding Author:**

28 Eberechi Nwogu-Onyemkpa
29

30 eberechi.nwogu-onyemkpa@bcm.edu
31

32 6501 Fannin St. NC 100, Houston, Texas 77030
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 **Abstract:**
8
9

10 **Objective:** Sickle cell disease (SCD) is a highly morbid condition notable for recurrent
11 hospitalizations due to vaso-occlusive crises and complications of end organ damage. Little is
12 known about the use of inpatient palliative care services in adult patients with SCD. This study
13 aims to evaluate inpatient palliative care use during SCD related hospitalizations overall and
14 during terminal hospitalizations. We hypothesize that use of palliative care is low in SCD
15 hospitalizations.
16
17
18
19
20
21
22
23

24
25 **Design:** A retrospective cross-sectional study utilizing data from the National Inpatient Sample
26 (NIS) from 2008-2017 was conducted.
27
28
29

30
31 **Setting:** U.S. hospitals from 47 states and the District of Columbia.
32
33

34 **Participants:** Patients >18 years old hospitalized with a primary or secondary ICD-9-CM and
35 ICD-10-CM diagnosis of SCD were included.
36
37
38
39

40 **Primary and secondary outcome measures:** Palliative care service utilization using ICD-9-CM
41 and ICD-10-CM diagnosis codes V66.7 and Z51.5.
42
43
44

45 **Results:** 987,555 SCD-related hospitalizations were identified, of which 4442 (0.45%) were
46 associated with palliative care service. Palliative care service utilization increased at a rate of
47 9.2% per year (CI, 5.6-12.9). NH-Black and Hispanic patients were 33% and 53% less likely to
48 have palliative care services compared to NH-White (OR 0.67; CI 0.45-0.99 and OR 0.47; CI,
49 0.26-0.84). Female patients (OR 0.40; CI, 0.21-0.76), Medicaid use (OR 0.40; CI, 0.21-0.78),
50
51
52
53
54
55
56
57

1
2
3 rural (OR 0.47; CI 0.28-0.79) and urban non-teaching hospitals (OR 0.61; CI 0.47-0.80) had
4
5 decreased likelihood of palliative care services use.
6
7

8
9 **Conclusion:** Utilization of palliative care during SCD-related hospitalizations is increasing but
10
11 remains low. Disparities associated with race and gender exist for use of palliative care services
12
13 during SCD related hospitalization. Further studies are needed to guide evidence-based palliative
14
15 care interventions for more comprehensive and equitable care of adult patients with SCD.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- Our study is the first of its kind to investigate palliative care utilization among SCD patients using a national database.
- ICD-9-CM and ICD-10-CM codes for palliative care are not specific to palliative care provided by a palliative care specialist as these codes also encompass patients who are in comfort care status.
- Our study investigated inpatient palliative care utilization and hence, our findings cannot be extrapolated to outpatient setting where patients with SCD patient receive most of their care.

Introduction:

Sickle cell disease (SCD) is a group of inherited red blood cell disorders in which abnormality in Hemoglobin (Hb) beta gene results in abnormal shape and sickling of red blood cells under stress. Physiologic manifestations of the illness arise from end organ ischemia, including acute pain from vaso-occlusive crises, cerebrovascular accident, acute chest syndrome, pulmonary hypertension, heart failure, renal failure, severe anemia, and recurrent infections.¹ Approximately 100,000 Americans predominantly of African (90%), Middle Eastern, and Mediterranean descent are affected by SCD.² Historically, SCD was a childhood disease – life expectancy for those with the disease was 20 years in 1970. Currently, life expectancy with SCD extends into adulthood but remains significantly lower than the general population (42-48 years), especially for sickle cell anemia—the most severe form of SCD.³ As an increasing number of people with SCD survive into adulthood, there is a rising need for effective transitions to adult medicine involving multidisciplinary care teams.⁴

SCD is a highly morbid condition. Recurrent hospitalization is common in SCD due to vaso-occlusive crises and complications of end organ damage.^{5 6} During their last year of life, people with SCD were hospitalized for an average of forty-two days over five admissions.⁷ Hospital admissions and ED visits increase sharply a month before death and most patients with SCD die in the hospital (63%) or emergency department (15%).⁷ Patients with SCD experience increased rates of depression and anxiety,^{8 9 10} chronic pain,¹¹ and decreased health-related quality of life.¹² Increased healthcare use¹³ and symptom burden are salient opportunities for palliative care intervention in this patient population. Palliative care provides holistic care for patients with serious chronic illnesses using a multidisciplinary team approach.¹⁴ Palliative care has been

1
2
3 shown to increase patient's quality of life and decrease health care cost^{15 16} but the impact of
4
5 palliative care on SCD is not well characterized.¹⁷
6
7

8 Furthermore, little is known about the use of *inpatient* palliative care services in adult patients
9
10 with SCD. To address this gap, we used national data to evaluate inpatient palliative care use
11
12 during SCD related hospitalizations overall and during terminal hospitalizations (hospitalizations
13
14 that resulted in patients' death in-hospital regardless of cause of death). We identified patient and
15
16 hospital characteristics associated with use of hospital-based palliative care services in SCD. We
17
18 hypothesize that use of palliative care is low in SCD hospitalizations.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods:

Data Source

Data from the 2008 to 2017 National Inpatient Sample (NIS), the largest all-payer, nationally representative inpatient database in the United States was used. The NIS is part of a group of databases developed by the Healthcare Utilization Project (HCUP) and sponsored by the Agency for Healthcare Research and Quality (AHRQ).¹⁸ This public database contains longitudinal data from a stratified sample of all discharges from U.S. hospitals from 47 states and the District of Columbia, excluding rehabilitation and long-term acute care hospitals, thereby estimating about a 20% sample of all hospital discharges. When weighted, each year, NIS contains data from about 35 million hospitalizations.

Study Population and Variables

The analysis was restricted to hospitalizations in adults aged 18 years and above. Diagnoses and procedures are coded using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes till the 3rd quarter of 2015, after which HCUP transitioned to ICD-10-CM format. To assess the study's primary exposure, we first scanned the diagnosis codes (the principal diagnosis and up to 29 secondary diagnoses) in each patient's discharge record for an indication of SCD (ICD-9-CM - 282.41, 282.42, 282.61, 282.62, 282.63, 282.64, 282.60, 282.68, 282.69; ICD-10-CM - D57.4x, D57.0x, D57.2x, D57.1x, D57.8x). The study's primary outcome was palliative care utilization which was identified using ICD-9-CM diagnosis code V66.7 and ICD-10-CM diagnosis code Z51.5. Covariates included in the study were socio-demographics for the patient which consisted of patients' age, race/ethnicity –

1
2
3 categorized as Non-Hispanic (NH)-White, NH-Black, Hispanic and NH-Others, sex, insurance
4 type – Medicare, Medicaid, private insurance, self-pay and others, median household income
5 based on zipcodes; and hospital characteristics such as hospital location, hospital type (urban vs.
6 rural and teaching vs. non-teaching), and hospital bed size.
7
8
9
10
11
12

13 Statistical Analysis

14
15
16
17 Since the NIS data was de-identified and publicly available, the study was approved as exempt
18 by the Institutional Review Board (IRB) of Baylor College of Medicine. All statistical tests were
19 two-tailed with the type-I error of 5% and were conducted using R version 3.5.1 (University of
20 Auckland, Auckland, New Zealand) and R Studio Version 1.1.423 (Boston, MA) and Joinpoint
21 Regression Program, version 4.7.0.0 (National Cancer Institute).
22
23
24
25
26
27
28
29

30 Temporal trends analyses were performed using Joinpoint regression technique, which allows to
31 examine the trend of an outcome (in this case, palliative care utilization) over the study period.¹⁹
32
33

34 The results are represented in the form of average annual percentage change (AAPC) and its
35 95% confidence interval (CI). We scrutinized the temporal trends in the rates of palliative care
36 utilization among SCD patients overall, and among those who died in-hospital. Next, we
37 examined the socio-demographic and hospitalization characteristics of patients with SCD and
38 those with SCD who utilized palliative care during their hospitalization. Prevalence rates of SCD
39 and palliative care utilization among SCD hospitalizations were calculated, stratified by patients'
40 race/ethnicity. Furthermore, we conducted adjusted survey logistic regression models to examine
41 the factors associated with palliative care utilization among all SCD hospitalizations and among
42 those which resulted in patients' death in-hospital.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patient and public involvement

Patients were not involved in this retrospective analysis of an anonymized national inpatient database.

For peer review only

Results:***Trends in the rate of palliative care utilization in SCD-related hospitalizations***

Between the study period of 2008 to 2018 the NIS contained 987,555 SCD-related hospitalizations of which 6,327 (0.64%) were terminal admissions. There were 4442 (0.45%) SCD-related hospitalizations associated with palliative care service. Figure 1 shows temporal trend in palliative care utilization. The rate of inpatient palliative care service utilization increased at 9.2% per year (95% CI, 5.6-12.9) for all SCD-related hospitalizations and 10.7% (95% CI, 3.4-18.5) for terminal hospitalizations.

Patient characteristics – SCD hospitalizations with palliative care utilization

Table 1 shows patient characteristics among SCD related hospitalizations and patients utilizing palliative care services. The prevalence of SCD-related hospitalization was highest among the 18-39 age group (9.7 per 1000 SCD hospitalizations) and decreased with increasing age. Conversely, the prevalence of inpatient palliative care use was highest in the oldest age group (34.8 per 1000 SCD hospitalization) and lowest in the 18-39 age group (3.8 per 1000 SCD hospitalization). In Figures 2 and 3 the prevalence of SCD-related hospitalization was most pronounced among NH-Blacks (20.7 per 1000 SCD hospitalization) and lowest in NH-Whites (0.1 per 1000 SCD hospitalization) while the frequency of inpatient palliative care services was highest in NH-Whites (12.6 per 1000 SCD hospitalizations) and lowest in Hispanics (3.6 per 1000 SCD hospitalization).

Regional and hospital characteristics – SCD hospitalizations with palliative care utilization

SCD hospitalization was lowest in the Northeast (1.4 per 1000 SCD hospitalization) but the prevalence of inpatient palliative care service was highest in this region (6.1 per 1000 SCD

1
2
3 hospitalization). Conversely the South region had the highest prevalence of SCD hospitalization
4 (4.3 per 1000 SCD hospitalization) but the lowest level of utilization of inpatient palliative care
5 services (3.6 per 1000 SCD hospitalization). Large and urban teaching hospitals had highest
6 level of inpatient palliative care service utilization (5.1 and 5.1 per 1000 SCD hospitalization,
7 respectively).

14 ***Factors associated with inpatient palliative care utilization in SCD***

18 Table 2 shows factors associated with inpatient palliative care utilization in SCD
19 hospitalizations. At end-of-life patients between 40-59 years were 81% more likely to utilize
20 palliative care services than patients 18-39 years old (odds ratio [OR], 1.81, 95% confidence
21 interval [CI], 1.19-2.75). NH-Black and Hispanic patients were 33% and 53% respectively less
22 likely to utilize inpatient palliative care services compared to NH-White (OR, 0.67; 95% CI,
23 0.45-0.99 and OR, 0.47; 95% CI, 0.26-0.84, respectively). Likewise, during terminal admissions
24 utilization of palliative care services was 67% and 72% less likely among NH-Black and
25 Hispanic patients, respectively when compared to NH-White (OR, 0.33; 95% CI, 0.16-0.68 and
26 OR, 0.28; 95% CI, 0.09-0.91, respectively). Female patients were 60% less likely to utilize
27 palliative care services than male patients (OR, 0.40; 95% CI, 0.21-0.76). Compared to routine
28 discharges, hospitalizations resulting in death and transfer to another health care facility were
29 associated with increased usage of inpatient palliative care services (OR, 39.36; 95% CI, 30.83-
30 49.98, and OR, 3.71; 95% CI, 2.73-5.03, respectively) while discharge against medical advice
31 (DAMA) was associated with decreased utilization of inpatient palliative care services (OR,
32 0.48; 95% CI 0.28-0.84).

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53 Patients with zip code in the highest income quartile were 58% more likely to utilize inpatient
54 palliative care services (OR, 1.58; 95% CI 1.02-2.45). Compared to Medicare patients, those
55
56
57

1
2
3 with Medicaid were 60% less likely (OR, 0.40; 95% CI, 0.21-0.78), while patients with private
4 insurance were 30% more likely (OR, 1.30; 95% CI, 0.93-1.59) to utilize palliative care services.
5
6 During terminal admissions, there was no significant difference in palliative care utilization
7
8 across different payors.
9
10

11
12
13
14
15
16 Patients admitted in a medium and large hospital were 47% and 91%, respectively more likely
17 (OR, 1.47; 95% CI, 1.02-2.12 and OR, 1.91; 95% CI, 1.30-2.82, respectively) to utilize palliative
18 care services than patients in small hospitals while patients admitted to rural or urban non-
19 teaching hospitals were less likely to utilize palliative care services than those in urban teaching
20 hospital (OR, 0.47; 95% CI 0.28-0.79) and OR, 0.61; 95% CI 0.47-0.80, respectively).
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion:

In this study of national trends, we found overall low utilization of palliative care services during SCD-related hospitalizations. Palliative care utilization was more likely among patients who are NH-White male, in higher income quartiles, with private insurance, who receive care in large academic hospitals in the northeast. NH-Black and Hispanic patients were less likely to utilize palliative care services especially during terminal hospitalizations.

While early palliative care has gained acceptance in cancer care,²⁰ its adoption in other serious life limiting conditions such as congestive heart failure, chronic kidney disease, and SCD lags. SCD has traditionally been viewed as a childhood disease as most patients did not survive to adulthood in the past. Currently, most patients with SCD survive to adulthood.³ Furthermore, some patients with SCD experience more complications and end organ damage from their disease than others resulting in shortened life expectancy. As such, several opportunities are present for palliative care intervention in provision of holistic care to patients earlier in the SCD course. Our study found higher prevalence of palliative care service usage in terminal admissions when compared to admissions with routine discharge or transfer to another level of care. This highlights the need for early provision of palliative care during non-terminal admissions, as patients benefit from the psychosocial support and symptom management from an interdisciplinary team, as well as early initiation of discussions regarding goals of care and patient's preference for end of life.

Our study showed most SCD-related hospitalizations and palliative care service usage were in the NH-Black group. However, further analysis accounting for covariates revealed that NH-Black patients were significantly less likely to utilize palliative care during hospitalization

1
2
3 compared to NH-white patients. Other studies have shown racial disparities in utilization of
4 palliative care services in other chronic diseases.^{21, 22} Furthermore, studies have shown that black
5 patients are less likely to utilize hospice services and more likely to received intensive life-
6 sustaining procedures at end of life compared to white patients.²³ Factors identified to drive this
7 racial disparity in hospice use include knowledge deficit,²⁴ mistrust of the health care system,²⁵
8 miscommunication and misunderstanding of treatment options,²⁶ and preference for more
9 aggressive care.²⁷ Similar studies are lacking to elucidate factors implicated for the racial
10 difference in non-hospice palliative care utilization across all life limiting diseases.²⁸ Palliative
11 care has a strong association with hospice with many patients and families unable to differentiate
12 the difference between the two. Therefore, the above factors identified are likely to also play a
13 role in racial difference observed in palliative care utilization in patient with chronic conditions
14 such as SCD. Further studies are needed to investigate patient and system factors associated
15 with racial difference in palliative care utilization in SCD.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34 Gender differences in utilization of inpatient palliative care services were found. Although male
35 and female patients had similar prevalence of SCD-related hospitalization, female patients were
36 60% less likely to utilize palliative care services. This finding is contrary to that of other studies
37 which show that women are more receptive to palliative care than men.²⁹ Pain is the most
38 prominent feature of SCD and hence it is plausible that inpatient palliative care services in SCD
39 hospitalizations involve pain management. Studies have shown that although most chronic pain
40 conditions are more prevalent in women than men, and women report greater pain then men after
41 invasive procedures, women receive less analgesia and are more likely to have their pain
42 attributed to psychological causes.³⁰ It is possible that palliative care consultants are more
43 frequently involved for specialist level pain management for male than female patients

1
2
3 accounting for the gender difference observed in our study. This finding requires further
4
5 investigation as the study by McClish et al. demonstrates that men and women with SCD report
6
7 similar pain experiences.³¹
8
9

10 We also found socioeconomic differences in utilization of palliative care in SCD similar to other
11
12 studies.^{22, 32, 33} Patients with zip codes in the highest income quartile and those with private
13
14 insurance were more likely to utilize palliative care, while patients with Medicaid were less
15
16 likely to utilize palliative care services. Insurance dictates patient's access to specialty care with
17
18 patients on Medicaid reporting more challenge than those with private insurance accessing
19
20 certain specialty care particularly in the outpatient setting.
21
22
23

24 Regional differences were detected in our study. The South region had the highest number of
25
26 SCD hospitalizations but the lowest prevalence of palliative care utilization. A patient in the
27
28 South was significant less likely to utilize palliative care services when compared to a patient in
29
30 the Northeast. This finding is notable as two of the three states (Florida, Texas, and New York)
31
32 with the highest population of SCD patients are in the South. Hospital characteristics were also
33
34 predictive of palliative care utilization with large, urban and teaching hospitals associated with
35
36 greater utilization of palliative care in SCD similar to findings from other studies.^{32 21 33} While
37
38 many sickle cell patients utilize larger, urban hospitals for their care,³⁴ this study highlights the
39
40 need for improvement in access to palliative care services across all settings in the US,
41
42 particularly in smaller, rural hospitals.
43
44
45
46
47

48 To our knowledge, our study is the first of its kind to investigate palliative care utilization among
49
50 SCD patients using a national data base. Limitations exist in our study one of which is the
51
52 validity of the ICD-9 and ICD-10 codes for identification of palliative care consultations.
53
54

55 Investigators have sought to validate these codes however these studies utilize data from a single
56
57
58
59
60

1
2
3 institution³⁵ or from the VA system.³⁶ Furthermore, the ICD-9 and ICD-10 codes for palliative
4 care are not specific to palliative care provided by a palliative care specialist as these codes also
5 encompass patients who are in comfort care status. Not all patients in comfort care are managed
6 by a palliative care specialist and as such it is difficult to delineate which hospitalizations were
7 indeed associated with the involvement of a palliative care specialist. In addition, our dataset
8 does not allow us to elucidate the nature of palliative care intervention provided during
9 admissions hence it is unclear if these interventions were for symptom management, goals of
10 care discussion, counseling and support, or transition to comfort care. Given utilization of
11 aggregate data in which a hospitalization is considered a single event, we are unable to identify
12 the number of patients who benefited from palliative care services as multiple admissions could
13 be associated with one patient. Lastly, our study investigated inpatient palliative care utilization
14 and hence, our findings cannot be extrapolated to outpatient setting where patients with SCD
15 patient receive most of their care.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34 SCD related morbidity and mortality has a significant impact on patient self-reported quality of
35 life outcomes and healthcare utilization and cost. Awareness of the complexity of SCD and its
36 end organ complications is needed at the provider level to highlight the need for early palliative
37 care involvement in this patient population. Early palliative care might guide patients' treatment
38 decisions and mitigate initiation of interventions that are not in line with a patients' wishes at the
39 end of life. Racial disparity in the utilization of palliative care by SCD patients should be
40 investigated with studies assessing knowledge of palliative care and barriers to palliative care
41 utilization by SCD patients. Furthermore, studies addressing system barriers to palliative care
42 utilization among minority patients are needed as the implication spans across other chronic
43 serious illnesses.

Acknowledgements

Conflict of Interest Disclosures: Authors without conflicts of interest, including relevant financial interests, activities, relationships, and affiliations.

Funding/Support: Research funding support was provided by the U.S. Department of Health and Human Services and Health Resources and Services Administration for Baylor College of Medicine Center of Excellence in Health Equity, Training, and Research (Grant No: D34HP31024). Additional support is provided to Dr. Naik from the Houston VA HSR&D Center for Innovations in Quality, Effectiveness, and Safety (CIN 13-413).

Authorship Contribution:

Eberechi Nwogu-Onyemkpa was involved in the conception of the study, interpretation of data, drafting, and revision of the manuscript.

Deepa Dongarwar was involved in the conception of the study, analysis of the data, drafting, and revision of the manuscript.

Hamisu Salihu was involved in the conception of the study and revision of the manuscript.

Chioma Akpati was involved in the interpretation of data and drafting of the manuscript.

Maricarmen Marroquin was involved in the interpretation of data and drafting of the manuscript.

Megan Abadom was involved in the interpretation of data and drafting of the manuscript.

Aanand D. Naik was involved in the conception of the study and revision of the manuscript.

References

1. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. *N Engl J Med*. Jul 20 2017;377(3):305. doi:10.1056/NEJMc1706325
2. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. *Am J Hematol*. Jan 2010;85(1):77-8. doi:10.1002/ajh.21570
3. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. *N Engl J Med*. Jun 9 1994;330(23):1639-44. doi:10.1056/NEJM199406093302303
4. Saulsberry AC, Porter JS, Hankins JS. A program of transition to adult care for sickle cell disease. *Hematology Am Soc Hematol Educ Program*. Dec 6 2019;2019(1):496-504. doi:10.1182/hematology.2019000054
5. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. *N Engl J Med*. May 18 1995;332(20):1317-22. doi:10.1056/NEJM199505183322001
6. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. *JAMA*. Apr 2 2003;289(13):1645-51. doi:10.1001/jama.289.13.1645
7. Johnston EE, Adesina OO, Alvarez E, et al. Acute Care Utilization at End of Life in Sickle Cell Disease: Highlighting the Need for a Palliative Approach. *J Palliat Med*. Jan 2020;23(1):24-32. doi:10.1089/jpm.2018.0649
8. Levenson JL, McClish DK, Dahman BA, et al. Depression and anxiety in adults with sickle cell disease: the PiSCES project. *Psychosom Med*. Feb 2008;70(2):192-6. doi:10.1097/PSY.0b013e31815ff5c5
9. Adam SS, Flahiff CM, Kamble S, Telen MJ, Reed SD, De Castro LM. Depression, quality of life, and medical resource utilization in sickle cell disease. *Blood Adv*. Oct 24 2017;1(23):1983-1992. doi:10.1182/bloodadvances.2017006940
10. Laurence B, George D, Woods D. Association between elevated depressive symptoms and clinical disease severity in African-American adults with sickle cell disease. *J Natl Med Assoc*. Mar 2006;98(3):365-9.
11. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. *Blood Adv*. Jun 23 2020;4(12):2656-2701. doi:10.1182/bloodadvances.2020001851
12. Lee S, Vania DK, Bhor M, Revicki D, Abogunrin S, Sarri G. Patient-Reported Outcomes and Economic Burden of Adults with Sickle Cell Disease in the United States: A Systematic Review. *Int J Gen Med*. 2020;13:361-377. doi:10.2147/IJGM.S257340
13. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. *Am J Hematol*. Jun 2009;84(6):323-7. doi:10.1002/ajh.21408
14. Sepulveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: the World Health Organization's global perspective. *J Pain Symptom Manage*. Aug 2002;24(2):91-6. doi:10.1016/s0885-3924(02)00440-2
15. Casarett D, Pickard A, Bailey FA, et al. Do palliative consultations improve patient outcomes? *J Am Geriatr Soc*. Apr 2008;56(4):593-9. doi:10.1111/j.1532-5415.2007.01610.x
16. Gade G, Venohr I, Conner D, et al. Impact of an inpatient palliative care team: a randomized control trial. *J Palliat Med*. Mar 2008;11(2):180-90. doi:10.1089/jpm.2007.0055
17. Ajayi TA, Edmonds KP, Thornberry K, Atayee RA. Palliative Care Teams as Advocates for Adults with Sickle Cell Disease. *J Palliat Med*. Feb 2016;19(2):195-201. doi:10.1089/jpm.2015.0268
18. NIS Database Documentation. Accessed June 1, 2021, <https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp>

19. National Cancer Institute. Joinpoint trend analysis software. Accessed June 1, 2021, <https://surveillance.cancer.gov/joinpoint/>
20. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med*. Aug 19 2010;363(8):733-42. doi:10.1056/NEJMoa1000678
21. Wen Y, Jiang C, Koncicki HM, et al. Trends and Racial Disparities of Palliative Care Use among Hospitalized Patients with ESKD on Dialysis. *J Am Soc Nephrol*. Sep 2019;30(9):1687-1696. doi:10.1681/ASN.2018121256
22. Lee K, Gani F, Canner JK, Johnston FM. Racial Disparities in Utilization of Palliative Care Among Patients Admitted With Advanced Solid Organ Malignancies. *Am J Hosp Palliat Care*. May 6 2020;1049909120922779. doi:10.1177/1049909120922779
23. Ornstein KA, Roth DL, Huang J, et al. Evaluation of Racial Disparities in Hospice Use and End-of-Life Treatment Intensity in the REGARDS Cohort. *JAMA Netw Open*. Aug 3 2020;3(8):e2014639. doi:10.1001/jamanetworkopen.2020.14639
24. Johnson KS, Kuchibhatla M, Tulsy JA. Racial differences in self-reported exposure to information about hospice care. *J Palliat Med*. Oct 2009;12(10):921-7. doi:10.1089/jpm.2009.0066
25. Cort MA. Cultural mistrust and use of hospice care: challenges and remedies. *J Palliat Med*. Feb 2004;7(1):63-71. doi:10.1089/109662104322737269
26. Mack JW, Paulk ME, Viswanath K, Prigerson HG. Racial disparities in the outcomes of communication on medical care received near death. *Arch Intern Med*. Sep 27 2010;170(17):1533-40. doi:10.1001/archinternmed.2010.322
27. Barnato AE, Anthony DL, Skinner J, Gallagher PM, Fisher ES. Racial and ethnic differences in preferences for end-of-life treatment. *J Gen Intern Med*. Jun 2009;24(6):695-701. doi:10.1007/s11606-009-0952-6
28. Johnson KS. Racial and ethnic disparities in palliative care. *J Palliat Med*. Nov 2013;16(11):1329-34. doi:10.1089/jpm.2013.9468
29. Saeed F, Hoerger M, Norton SA, Guancial E, Epstein RM, Duberstein PR. Preference for Palliative Care in Cancer Patients: Are Men and Women Alike? *J Pain Symptom Manage*. Jul 2018;56(1):1-6 e1. doi:10.1016/j.jpainsymman.2018.03.014
30. Gott M, Morgan T, Williams L. Gender and palliative care: a call to arms. *Palliat Care Soc Pract*. 2020;14:2632352420957997. doi:10.1177/2632352420957997
31. McClish DK, Levenson JL, Penberthy LT, et al. Gender differences in pain and healthcare utilization for adult sickle cell patients: The PiSCES Project. *J Womens Health (Larchmt)*. Mar 2006;15(2):146-54. doi:10.1089/jwh.2006.15.146
32. Patel AA, Walling AM, Ricks-Oddie J, May FP, Saab S, Wenger N. Palliative Care and Health Care Utilization for Patients With End-Stage Liver Disease at the End of Life. *Clin Gastroenterol Hepatol*. Oct 2017;15(10):1612-1619 e4. doi:10.1016/j.cgh.2017.01.030
33. Yu KG, Shen JJ, Kim PC, et al. Trends of Hospital Palliative Care Utilization and Its Associated Factors Among Patients With Systemic Lupus Erythematosus in the United States From 2005 to 2014. *Am J Hosp Palliat Care*. Mar 2020;37(3):164-171. doi:10.1177/1049909119891999
34. Fingar KR, Owens PL, Reid LD, Mistry KB, Barrett ML. Characteristics of Inpatient Hospital Stays Involving Sickle Cell Disease, 2000-2016: Statistical Brief #251. *Healthcare Cost and Utilization Project (HCUP) Statistical Briefs*. 2006.
35. Hua M, Li G, Clancy C, Morrison RS, Wunsch H. Validation of the V66.7 Code for Palliative Care Consultation in a Single Academic Medical Center. *J Palliat Med*. Apr 2017;20(4):372-377. doi:10.1089/jpm.2016.0363
36. Feder SL, Redeker NS, Jeon S, et al. Validation of the ICD-9 Diagnostic Code for Palliative Care in Patients Hospitalized With Heart Failure Within the Veterans Health Administration. *Am J Hosp Palliat Care*. Jul 2018;35(7):959-965. doi:10.1177/1049909117747519

Table 1: Patient characteristics among SCD-related hospitalizations and among those with SCD who utilized palliative care during their hospitalization

	Total N=307709982	SCD related hospitalizations N=987555	Prevalence of SCD-related hospitalizations (per 1000 hospitalizations)	Hospitalizations among patients with SCD receiving palliative care N=4442	Prevalence of palliative care usage (per 1000 SCD hospitalizations)
Age Group					
18-39 years	75567499	733837	9.7	2824	3.8
40-59 years	78526326	214939	2.7	1160	5.4
60-79 years	101611492	35362	0.3	339	9.6
80+ years	52004665	3417	0.1	119	34.8
Race/Ethnicity					
NH-White	192567014	16962	0.1	214	12.6
NH-Black	41490748	857006	20.7	3773	4.4
Hispanic	29897432	32676	1.1	116	3.6
Others	17422072	23026	1.3	157	6.8
Missing	26332714	57883	2.2	181	3.1
Sex					
Male	125745784	427285	3.4	1921	4.5
Female	181778482	559845	3.1	2521	4.5
Missing	185716	424	2.3	0	0.0
Discharge Status					
Routine	202797074	853218	4.2	2619	3.1
Transfer	55186460	37409	0.7	447	11.9
Died	6740712	6327	0.9	685	108.3
DAMA	3847845	44520	11.6	69	1.5
Other	38933666	45507	1.2	622	13.7
Missing	204225	573	2.8	0	0.0
Zip code income quartile					
Lowest quartile	89460128	478674	5.4	2053	4.3
2nd quartile	78497949	219619	2.8	801	3.6
3rd quartile	71474969	163233	2.3	836	5.1
Highest quartile	61340502	100769	1.6	703	7.0
Missing	6936433	25259	3.6	48	1.9
Primary Payer					
Medicare	141357438	315777	2.2	1736	5.5
Medicaid	50563783	428967	8.5	1725	4.0
Private Insurance	88933878	170459	1.9	671	3.9
Self-Pay	26247689	70526	2.7	304	4.3
Missing	607194	1825	3.0	5	2.7
Hospital Characteristics					
Hospital Region					
Northeast	33888883	46282	1.4	1226	6.1
Midwest	107572349	234180	2.2	1014	5.4
South	164884575	701680	4.3	1820	3.6

1						
2						
3	West	1364173	5411	4.0	382	4.4
4						
5	Hospital Bed Size					
6	Small	46455596	114366	2.5	331	2.9
7	Medium	81563430	258481	3.2	998	3.9
8	Large	178326782	609296	3.4	3108	5.1
9	Missing	1364173	5411	4.0	4	0.7
10						
11	Hospital Location and Teaching Status					
12						
13	Rural	33888883	46282	1.4	96	2.1
14	Urban non-teaching	107572349	234180	2.2	749	3.2
15	Urban teaching	164884575	701680	4.3	3591	5.1
16	Missing	1364173	5411	4.0	4	0.7

17 SCD-Sickle Cell Disease

18 NH-Non-Hispanic

19 DAMA-Discharged Against Medical Advice

20 Prevalence is the rate of the outcome (SCD or palliative care usage) among each patient characteristics

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Table 2: Factors associated with palliative care utilization in SCD patients – overall and among those who died in-hospital

	Palliative care utilization in SCD hospitalizations	Palliative care utilization among SCD patients who died in-hospital
	OR(95% CI)	OR(95% CI)
Race/Ethnicity		
NH-White	reference	reference
NH-Black	0.67(0.45-0.99)*	0.33(0.16-0.68)*
Hispanic	0.47(0.26-0.84)*	0.28(0.09-0.91)*
Others	0.83(0.49-1.39)	0.41(0.12-1.42)
Age Group		
18-39 years	reference	reference
40-59 years	0.98(0.81-1.18)	1.81(1.19-2.75)*
60-79 years	0.95(0.70-1.30)	1.13(0.60-2.12)
80+ years	2.34(1.41-3.88)*	2.29(0.79-6.64)
Sex		
Male	reference	reference
Female	0.40(0.21-0.76)*	1.45(1.00-2.11)
Discharge Status		
Routine	reference	reference
Transfer	3.71(2.73-5.03)*	—
Died	39.26(30.83-49.98)*	—
DAMA	0.48(0.28-0.84)*	—
Other	4.14(3.20-5.35)*	—
Zip code income quartile		
Lowest quartile	reference	reference
2nd quartile	0.89(0.71-1.11)	0.69(0.42-1.14)
3rd quartile	1.24(0.85-1.80)	0.48(0.25-0.91)*
Highest quartile	1.58(1.02-2.45)*	1.46(0.79-2.71)
Primary Payer		
Medicare	reference	reference
Medicaid	0.40(0.21-0.78)*	0.72(0.21-2.48)
Private Insurance	1.30(1.02-1.65)*	1.03(0.59-1.79)
Self-Pay	1.22(0.93-1.59)	1.12(0.64-1.99)
Hospital Characteristics		
Hospital Region		
Northeast	reference	reference
Midwest	1.00(0.57-1.75)	1.18(0.57-2.46)
South	0.69(0.42-1.11)	1.47(0.78-2.78)
West	0.72(0.40-1.31)	1.63(0.77-3.41)
Hospital Bed Size		
Small	reference	reference
Medium	1.47(1.02-2.12)*	1.18(0.57-2.44)
Large	1.91(1.30-2.82)*	1.52(0.78-2.96)

Hospital Location and Teaching Status

Urban teaching	reference	reference
Rural	0.47(0.28-0.79)*	0.75(0.33-1.73)
Urban non-teaching	0.61(0.47-0.80)*	0.63(0.40-0.99)

SCD-Sickle Cell Disease

NH-Non-Hispanic

DAMA-Discharged Against Medical Advice

OR- odds ratio, CI- confidence interval

Figure legend/caption

Figure 1: Temporal trends in the rates of palliative care utilization represented as average annual percentage change (AAPC). Rate of inpatient palliative care service utilization increased at 9.2% per year (95% CI, 5.6-12.9) for all SCD-related hospitalizations and 10.7% (95% CI, 3.4-18.5) for terminal hospitalizations.

Figure 2: Prevalence of SCD-related hospitalization was highest among NH-Blacks (20.7 per 1000 SCD hospitalization) and lowest in NH-Whites (0.1 per 1000 SCD hospitalization).

Figure 3: Prevalence of inpatient palliative services was highest in NH-Whites (12.6 per 1000 SCD hospitalizations) and lowest in Hispanics (3.6 per 1000 SCD hospitalization).

Figure 1: Trends in the rates of palliative care utilization in SCD-related hospitalizations, overall and among those who died in-hospital






Figure 2- Prevalence rates of SCD-related hospitalizations (per 1000 hospitalizations) by race/ethnicity



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3 – Prevalence rates of palliative care usage in SCD-related hospitalizations (per 1000 SCD hospitalizations) by race/ethnicity



For peer review only

Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5,6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7,8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7,8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7,8
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	
Outcome data	15*	Report numbers of outcome events or summary measures	

Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

1			
2	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
3			
4			
5			
6			
7			
8			
9			
10			
11	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
12			
13			
14	Discussion		
15	Key results	18	Summarise key results with reference to study objectives
16	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
17			
18			
19			
20	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
21			
22			
23			
24	Generalisability	21	Discuss the generalisability (external validity) of the study results
25			
26	Other information		
27	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
28			
29			
30			

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057361.R1
Article Type:	Original research
Date Submitted by the Author:	09-Mar-2022
Complete List of Authors:	Nwogu-Onyemkpa, Eberechi; Baylor College of Medicine, Department of Medicine, Center of Excellence in Health Equity, Training and Research; Baylor College of Medicine, Section of Geriatrics and Palliative Medicine Dongarwar, Deepa; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Salihu, HM; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Akpati, Lois; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Marroquin, Maricarmen; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Abadom, Megan; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Naik, Aanand; UTHealth School of Public Health, Management, Policy and Community Health; Michael E DeBakey VA Medical Center, Houston Center for Innovations in Quality, Effectiveness, and Safety
Primary Subject Heading:	Palliative care
Secondary Subject Heading:	Haematology (incl blood transfusion)
Keywords:	Adult palliative care < PALLIATIVE CARE, HAEMATOLOGY, Anaemia < HAEMATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Title: Inpatient palliative care use by patients with sickle cell disease: a**
4 **retrospective cross-sectional study**
5
6

7 **Eberechi Nwogu-Onyemkpa, MD^{1,2}, Deepa Dongarwar, MS¹, Hamisu M. Salihu, MD,**
8 **PhD¹, Lois Akpati, BS¹, Maricarmen Marroquin, BS¹, Megan Abadom, BS¹, Aanand D.**
9 **Naik, MD^{3,4}**
10

11 **Affiliations:** ¹Baylor College of Medicine Center of Excellence in Health Equity, Training and
12 Research, Houston, Texas

13
14 ²Department of Medicine, Section of Geriatrics and Palliative Medicine, Baylor College of
15 Medicine, Houston, Texas

16
17 ³UTHealth Consortium on Aging; and Department of Management, Policy and Community
18 Health, UT School of Public Health, Houston, Texas

19
20 ⁴Houston Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA
21 Medical Center, Houston, Texas
22
23
24
25
26
27

28 Word count: 3,059
29
30

31 **Corresponding Author:**

32 Eberechi Nwogu-Onyemkpa

33 eberechi.nwogu-onyemkpa@bcm.edu

34 6501 Fannin St. NC 100, Houston, Texas 77030
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 **Abstract:**
8
9

10 **Objective:** Sickle cell disease (SCD) is a highly morbid condition notable for recurrent
11 hospitalizations due to vaso-occlusive crises and complications of end organ damage. Little is
12 known about the use of inpatient palliative care services in adult patients with SCD. This study
13 aims to evaluate inpatient palliative care use during SCD related hospitalizations overall and
14 during terminal hospitalizations. We hypothesize that use of palliative care is low in SCD
15 hospitalizations.
16
17
18
19
20
21
22
23

24
25 **Design:** A retrospective cross-sectional study utilizing data from the National Inpatient Sample
26 (NIS) from 2008-2017 was conducted.
27
28
29

30
31 **Setting:** U.S. hospitals from 47 states and the District of Columbia.
32
33

34 **Participants:** Patients >18 years old hospitalized with a primary or secondary ICD-9-CM and
35 ICD-10-CM diagnosis of SCD were included.
36
37
38
39

40 **Primary and secondary outcome measures:** Palliative care service usage (documented by
41 ICD-9-CM and ICD-10-CM diagnosis codes V66.7 and Z51.5).
42
43
44

45 **Results:** 987,555 SCD-related hospitalizations were identified, of which 4442 (0.45%) received
46 palliative care service. Palliative care service usage increased at a rate of 9.2% per year (CI, 5.6-
47 12.9). NH-Black and Hispanic patients were 33% and 53% less likely to have palliative care
48 services compared to NH-White (OR 0.67; CI 0.45-0.99 and OR 0.47; CI, 0.26-0.84). Female
49 patients (OR 0.40; CI, 0.21-0.76), Medicaid use (OR 0.40; CI, 0.21-0.78), rural (OR 0.47; CI
50
51
52
53
54
55
56
57
58
59
60

1
2
3 0.28-0.79) and urban non-teaching hospitals (OR 0.61; CI 0.47-0.80) had decreased likelihood of
4 palliative care services use.
5
6

7
8
9 **Conclusion:** Usage of palliative care during SCD-related hospitalizations is increasing but
10 remains low. Disparities associated with race and gender exist for use of palliative care services
11 during SCD related hospitalization. Further studies are needed to guide evidence-based palliative
12 care interventions for more comprehensive and equitable care of adult patients with SCD.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- Our study is the first of its kind to investigate palliative care use among SCD patients using a national database.
- ICD-9-CM and ICD-10-CM codes for palliative care are not specific to palliative care provided by a palliative care specialist as these codes also encompass patients who are in comfort care status.
- Our study investigated inpatient palliative care usage and hence, our findings cannot be extrapolated to outpatient setting where patients with SCD patient receive most of their care.

Introduction:

Sickle cell disease (SCD) is a group of inherited red blood cell disorders in which abnormality in Hemoglobin (Hb) beta gene results in abnormal shape and sickling of red blood cells under stress. Physiologic manifestations of the illness arise from end organ ischemia, including acute pain from vaso-occlusive crises, cerebrovascular accident, acute chest syndrome, pulmonary hypertension, heart failure, renal failure, severe anemia, and recurrent infections.¹ Approximately 100,000 Americans predominantly of African (90%), Middle Eastern, and Mediterranean descent are affected by SCD.² Historically, SCD was a childhood disease – life expectancy for those with the disease was 20 years in 1970. Currently, life expectancy with SCD extends into adulthood (42-48 years) but remains significantly lower than the general population, especially for sickle cell anemia—the most severe form of SCD.³ As an increasing number of people with SCD survive into adulthood, there is a rising need for effective transitions to adult medicine involving multidisciplinary care teams.⁴

SCD is a highly morbid condition. Recurrent hospitalization is common in SCD due to vaso-occlusive crises and complications of end organ damage.^{5 6} During their last year of life, people with SCD were hospitalized for an average of forty-two days over five admissions.⁷ Hospital admissions and ED visits increase sharply a month before death and most patients with SCD die in the hospital (63%) or emergency department (15%).⁷ Patients with SCD experience increased rates of depression and anxiety,^{8 9 10} chronic pain,¹¹ and decreased health-related quality of life.¹² Increased healthcare use¹³ and symptom burden are salient opportunities for palliative care intervention in this patient population. Palliative care provides holistic care for patients with serious chronic illnesses using a multidisciplinary team approach.¹⁴ Palliative care has been

1
2
3 shown to increase patient's quality of life and decrease health care cost^{15 16} but the impact of
4
5 palliative care on SCD is not well characterized.¹⁷
6
7

8 Furthermore, little is known about the use of *inpatient* palliative care services in adult patients
9
10 with SCD. To address this gap, we used national data to evaluate inpatient palliative care use
11
12 during SCD related hospitalizations overall and during terminal hospitalizations (hospitalizations
13
14 that resulted in patients' death in-hospital regardless of cause of death). We identified patient and
15
16 hospital characteristics associated with use of hospital-based palliative care services in SCD. We
17
18 hypothesize that use of palliative care is low in SCD hospitalizations.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods:

Data Source

Data from the 2008 to 2017 National Inpatient Sample (NIS), the largest all-payer, nationally representative inpatient database in the United States was used. The NIS is part of a group of databases developed by the Healthcare Utilization Project (HCUP) and sponsored by the Agency for Healthcare Research and Quality (AHRQ).¹⁸ This public database contains longitudinal data from a stratified sample of all discharges from U.S. hospitals from 47 states and the District of Columbia, excluding rehabilitation and long-term acute care hospitals, thereby estimating about a 20% sample of all hospital discharges. When weighted, each year, NIS contains data from about 35 million hospitalizations.

Study Population and Variables

The analysis was restricted to hospitalizations in adults aged 18 years and above. Diagnoses and procedures are coded using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes till the 3rd quarter of 2015, after which HCUP transitioned to ICD-10-CM format. To assess the study's primary exposure, we first scanned the diagnosis codes (the principal diagnosis and up to 29 secondary diagnoses) in each patient's discharge record for an indication of SCD (ICD-9-CM - 282.41, 282.42, 282.61, 282.62, 282.63, 282.64, 282.60, 282.68, 282.69; ICD-10-CM - D57.4x, D57.0x, D57.2x, D57.1x, D57.8x). The study's primary outcome was palliative care use which was identified using ICD-9-CM diagnosis code V66.7 and ICD-10-CM diagnosis code Z51.5. There were no changes in the criteria for palliative care code with the transition from ICD-9-CM to ICD-10-CM. Covariates included in the

1
2
3 study were socio-demographics for the patient which consisted of patients' age, race/ethnicity –
4 categorized as Non-Hispanic (NH)-White, NH-Black, Hispanic and NH-Others, sex, insurance
5 type – Medicare, Medicaid, private insurance, self-pay and others, median household income
6 based on zipcodes; and hospital characteristics such as hospital location, hospital type (urban vs.
7 rural and teaching vs. non-teaching), and hospital bed size.
8
9
10
11
12
13

14 15 16 Statistical Analysis

17
18
19 Since the NIS data was de-identified and publicly available, the study was approved as exempt
20 by the Institutional Review Board (IRB) of Baylor College of Medicine. All statistical tests were
21 two-tailed with the type-I error of 5% and were conducted using R version 3.5.1 (University of
22 Auckland, Auckland, New Zealand) and R Studio Version 1.1.423 (Boston, MA) and Joinpoint
23 Regression Program, version 4.7.0.0 (National Cancer Institute).
24
25
26
27
28
29

30
31
32 Temporal trends analyses were performed using Joinpoint regression technique, which enables
33 examination of the trend of an outcome (in this case, palliative care use) over the study period.¹⁹
34

35
36 The results are represented in the form of average annual percentage change (AAPC) and its
37 95% confidence interval (CI). We scrutinized the temporal trends in the rates of palliative care
38 use among SCD patients overall, and among those who died in-hospital. Next, we examined the
39 socio-demographic and hospitalization characteristics of patients with SCD and those with SCD
40 who received palliative care during their hospitalizations. Prevalence rates of SCD and palliative
41 care use among SCD hospitalizations were calculated, stratified by patients' race/ethnicity.
42
43
44
45
46
47
48
49

50 Furthermore, after excluding records with missing values in model variables, we conducted
51 adjusted survey logistic regression models to examine the patient socio-demographic and
52
53
54
55
56
57
58
59

1
2
3 hospitalization characteristics (exposures) associated with palliative care use (outcome variable)
4
5 among all SCD hospitalizations and among those which resulted in patients' death in-hospital.
6
7

8 9 **Patient and public involvement**

10
11 Patients were not involved in this retrospective analysis of an anonymized national inpatient
12
13 database.
14
15

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Results:***Trends in the rate of palliative care usage in SCD-related hospitalizations***

Between the study period of 2008 to 2018 the NIS contained 987,555 SCD-related hospitalizations of which 6,327 (0.64%) were terminal admissions. There were 4442 (0.45%) SCD-related hospitalizations that received palliative care service. Figure 1 shows temporal trends in palliative care usage. The rate of inpatient palliative care service use increased at an average of 9.2% per year (95% CI, 5.6-12.9) for all SCD-related hospitalizations – from 2.86 per 1000 hospitalizations in 2008 to 6.32 per 1000 hospitalizations in 2017; and an average of 10.7% (95% CI, 3.4-18.5) for terminal hospitalizations – 6.34 per 1000 hospitalizations in 2008 to 15.82 per 1000 hospitalizations in 2017.

Patient characteristics – SCD hospitalizations with palliative care usage

Table 1 shows patient characteristics for SCD related hospitalizations and patients utilizing palliative care services. The prevalence of SCD-related hospitalization was highest among the 18-39 age group (9.7 per 1000 SCD hospitalizations) and decreased with increasing age. Conversely, the prevalence of inpatient palliative care use was highest in the oldest age group (34.8 per 1000 SCD hospitalization) and lowest in the 18-39 age group (3.8 per 1000 SCD hospitalizations). The prevalence of SCD-related hospitalization was highest among NH-Blacks (20.7 per 1000 SCD hospitalizations) and lowest in NH-Whites (0.1 per 1000 SCD hospitalizations) while the prevalence of inpatient palliative care services was highest in NH-Whites (12.6 per 1000 SCD hospitalizations) and lowest in Hispanics (3.6 per 1000 SCD hospitalizations).

Regional and hospital characteristics – SCD hospitalizations with palliative care usage

1
2
3 SCD hospitalization was lowest in the Northeast (1.4 per 1000 SCD hospitalizations) but the
4 prevalence of inpatient palliative care service was highest in this region (6.1 per 1000 SCD
5 hospitalizations). Conversely the South region had the highest prevalence of SCD hospitalization
6 (4.3 per 1000 SCD hospitalizations) but the lowest level of usage of inpatient palliative care
7 services (3.6 per 1000 SCD hospitalizations). Large and urban teaching hospitals had the highest
8 prevalence of SCD hospitalization (3.4 and 4.3 per 1000 hospitalizations, respectively) and
9 highest level of inpatient palliative care service use (5.1 and 5.1 per 1000 SCD hospitalizations,
10 respectively).
11
12
13
14
15
16
17
18
19
20
21

22 ***Factors associated with inpatient palliative care usage in SCD***

23
24
25 Table 2 shows factors associated with inpatient palliative care usage in SCD hospitalizations.
26
27 During terminal hospitalizations patients between 40-59 years were 81% more likely to receive
28 palliative care services than patients 18-39 years old (odds ratio [OR], 1.81, 95% confidence
29 interval [CI], 1.19-2.75). NH-Black and Hispanic patients were 33% and 53% respectively less
30 likely to receive inpatient palliative care services compared to NH-White (OR, 0.67; 95% CI,
31 0.45-0.99 and OR, 0.47; 95% CI, 0.26-0.84, respectively). Likewise, during terminal admissions
32 usage of palliative care services was 67% and 72% less likely among NH-Black and Hispanic
33 patients, respectively when compared to NH-White (OR, 0.33; 95% CI, 0.16-0.68 and OR, 0.28;
34 95% CI, 0.09-0.91, respectively). Female patients were 60% less likely to receive palliative care
35 services than male patients (OR, 0.40; 95% CI, 0.21-0.76). Compared to routine discharges,
36 hospitalizations resulting in death and transfer to another health care facility were associated
37 with increased usage of inpatient palliative care services (OR, 39.36; 95% CI, 30.83-49.98, and
38 OR, 3.71; 95% CI, 2.73-5.03, respectively) while discharge against medical advice (DAMA) was
39 associated with decreased use of inpatient palliative care services (OR, 0.48; 95% CI 0.28-0.84).
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Patients with zip code in the highest income quartile were 58% more likely to receive inpatient
4 palliative care services (OR, 1.58; 95% CI 1.02-2.45) than those in the lowest quartile.

5
6
7 Compared to Medicare patients, those with Medicaid were 60% less likely (OR, 0.40; 95% CI,
8 0.21-0.78), while patients with private insurance were 30% more likely (OR, 1.30; 95% CI, 0.93-
9 1.59) to receive palliative care services. During terminal admissions, there were no significant
10 differences in palliative care usage across different payors.
11
12
13
14
15
16
17
18
19

20 Patients admitted in a medium or large hospital were 47% and 91%, respectively more likely
21 (OR, 1.47; 95% CI, 1.02-2.12 and OR, 1.91; 95% CI, 1.30-2.82, respectively) to receive
22 palliative care services than patients in small hospitals while patients admitted to rural or urban
23 non-teaching hospitals were less likely to receive palliative care services than those in urban
24 teaching hospital (OR, 0.47; 95% CI 0.28-0.79 and OR, 0.61; 95% CI 0.47-0.80, respectively).
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion:

In this study of national trends, we found overall low usage of palliative care services during SCD-related hospitalizations. Palliative care use was more likely among patients who are NH-White male, in higher income quartiles, with private insurance, who receive care in large academic hospitals in the northeast. NH-Black and Hispanic patients were less likely to receive palliative care services especially during terminal hospitalizations.

While early palliative care has gained acceptance in cancer care,²⁰ its adoption in other serious life limiting conditions such as congestive heart failure, chronic kidney disease, and SCD lags. SCD has traditionally been viewed as a childhood disease as most patients did not survive to adulthood in the past. Currently, most patients with SCD survive to adulthood.³ Furthermore, some SCD patients experience complications and end organ damage from their disease resulting in a shortened life expectancy than the general population. Our study found higher prevalence of palliative care service usage in terminal admissions when compared to admissions with routine discharge or transfer to another level of care. This highlights an opportunity earlier in the progression of SCD for palliative care involvement, facilitating more holistic care of patients. Earlier initiation of palliative care grants patients psychosocial support and symptom management from an interdisciplinary team,²¹ as well as honest discussions regarding goals of care and patient's preference for end of life.

Our study showed most SCD-related hospitalizations and palliative care service usage were in the NH-Black group. However, further analysis accounting for covariates revealed that NH-Black patients were significantly less likely to receive palliative care during hospitalization compared to NH-white patients. Notably, race/ethnicity was the only factor associated with

1
2
3 palliative care use in both SCD and terminal hospitalizations. Other studies have shown racial
4
5 disparities in use of palliative care services in other chronic diseases.^{22,23} Furthermore, studies
6
7 have shown that black patients are less likely to use hospice services and more likely to receive
8
9 intensive life-sustaining procedures at end of life compared to white patients.²⁴ Factors
10
11 identified to drive this racial disparity in hospice use include knowledge deficits,²⁵ mistrust of the
12
13 health care system,²⁶ miscommunication and misunderstanding of treatment options,²⁷ and
14
15 preference in more aggressive care.²⁸ Similar studies are lacking to elucidate factors implicated
16
17 in the racial difference in non-hospice palliative care usage across all life limiting diseases.²⁹
18
19 Palliative care has a strong perceived association with hospice with many patients and families
20
21 unable to differentiate between the two. Therefore, the above factors identified are likely to also
22
23 play a role in racial differences observed in palliative care use in patients with chronic conditions
24
25 such as SCD. Further studies are needed to investigate patient and system factors associated
26
27 with racial differences in palliative care usage in SCD.
28
29
30
31

32
33 Gender differences in use of inpatient palliative care services were found. Although male and
34
35 female patients had similar prevalence of SCD-related hospitalization, female patients were 60%
36
37 less likely to receive palliative care services. This finding is contrary to that of other studies
38
39 which show that women are more receptive to palliative care than men.³⁰ Pain is the most
40
41 prominent feature of SCD and hence it is plausible that inpatient palliative care services in SCD
42
43 hospitalizations primarily involve pain management. Studies have shown that although most
44
45 chronic pain conditions are more prevalent in women than men, and women report greater pain
46
47 than men after invasive procedures, women receive less analgesia and are more likely to have
48
49 their pain attributed to psychological causes.³¹ It is possible that palliative care consultants are
50
51 more frequently involved for specialist level pain management for male than female patients
52
53
54
55
56
57
58
59
60

1
2
3 accounting for the gender difference observed in our study. This finding requires further
4
5 investigation as the study by McClish et al. demonstrates that men and women with SCD report
6
7 similar pain experiences.³²
8
9

10 We also found socioeconomic differences in the usage of palliative care in SCD similar to other
11
12 diseases.^{23,33,34} Patients with zip codes in the highest income quartile and those with private
13
14 insurance were more likely to receive palliative care, while patients with Medicaid were less
15
16 likely to receive palliative care services. Insurance dictates patient's access to specialty care with
17
18 patients on Medicaid reporting more challenge than those with private insurance accessing
19
20 certain specialty care particularly in the outpatient setting.^{35,36}
21
22
23

24 Regional differences were detected in our study. The South region had the highest number of
25
26 SCD hospitalizations but the lowest prevalence of palliative care use. This finding is notable as
27
28 two of the three states (Florida, Texas, and New York) with the highest population of SCD
29
30 patients are in the South. Hospital characteristics were also predictive of palliative care usage
31
32 with medium, large and urban teaching hospitals associated with greater usage of palliative care
33
34 in SCD similar to findings from other studies.^{33 22 34} While many sickle cell patients use larger,
35
36 urban hospitals for their care,³⁷ this study highlights the need for improvement in access to
37
38 palliative care services across all settings in the US, particularly in small and rural hospitals.
39
40
41
42

43 To our knowledge, our study is the first of its kind to investigate palliative care use among SCD
44
45 patients using a national data base. Limitations exist in our study one of which is the validity of
46
47 the ICD-9 and ICD-10 codes for identification of palliative care consultations. Investigators have
48
49 sought to validate these codes however these studies utilize data from a single institution³⁸ or
50
51 from the VA system.³⁹ Furthermore, the ICD-9 and ICD-10 codes for palliative care are not
52
53 specific to palliative care provided by a palliative care specialist as these codes also encompass
54
55
56
57
58
59
60

1
2
3 patients who are in comfort care status. Not all patients in comfort care are managed by a
4
5 palliative care specialist and as such it is difficult to delineate which hospitalizations were indeed
6
7 associated with the involvement of a palliative care specialist. In addition, our dataset does not
8
9 allow us to elucidate the nature of palliative care interventions provided during admissions hence
10
11 it is unclear if these interventions were for symptom management, goals of care discussion,
12
13 counseling and support, or transition to comfort care. Given utilization of aggregate data in
14
15 which a hospitalization is considered a single event, we are unable to identify the number of
16
17 patients who benefited from palliative care services as multiple admissions could be associated
18
19 with one patient. Lastly, our study investigated inpatient palliative care use and hence, our
20
21 findings cannot be extrapolated to outpatient settings where patients with SCD patient receive
22
23 most of their care. As such, we suspect that our study overestimates the prevalence of palliative
24
25 care usage in SCD.
26
27
28
29

30
31 SCD related morbidity and mortality have a significant impact on patient self-reported quality of
32
33 life outcomes and healthcare utilization and cost. Early palliative care might guide patients'
34
35 treatment decisions and mitigate initiation of interventions that are not in line with a patients'
36
37 wishes at the end of life. Early palliative care also has the potential to improve symptom
38
39 management and consequently improve quality of life for individuals with SCD. Studies
40
41 exploring barriers and facilitators to early palliative care at the provider (SCD providers,
42
43 palliative care specialists), patient, and system levels do not exist and are needed for future
44
45 recommendation for PC interventions in this population. Racial disparity in the use of palliative
46
47 care by SCD patients should be investigated with studies assessing knowledge of palliative care
48
49 and barriers to palliative care use by SCD patients. Furthermore, studies addressing system
50
51
52
53
54
55
56
57
58
59
60

1
2
3 barriers to palliative care use among minority patients are needed as the implication spans across
4
5 other life limiting illnesses.
6
7

8 **Acknowledgements**

9
10
11
12 **Conflict of Interest Disclosures:** Authors without conflicts of interest, including relevant
13
14 financial interests, activities, relationships, and affiliations.
15
16

17
18 **Funding/Support:** Research funding support was provided by the U.S. Department of Health
19
20 and Human Services and Health Resources and Services Administration for Baylor College of
21
22 Medicine Center of Excellence in Health Equity, Training, and Research (Grant No:
23
24 D34HP31024). Additional support is provided to Dr. Naik from the Houston VA HSR&D Center
25
26 for Innovations in Quality, Effectiveness, and Safety (CIN 13-413).
27
28
29

30 **Authorship Contribution:**

31
32
33 Eberechi Nwogu-Onyemkpa was involved in the conception of the study, interpretation of data,
34
35 drafting, and revision of the manuscript.
36
37

38
39 Deepa Dongarwar was involved in the conception of the study, analysis of the data, drafting, and
40
41 revision of the manuscript.
42
43

44 Hamisu Salihu was involved in the conception of the study and revision of the manuscript.
45
46

47 Chioma Akpati was involved in the interpretation of data and drafting of the manuscript.
48
49

50 Maricarmen Marroquin was involved in the interpretation of data, drafting and revision of the
51
52 manuscript.
53
54

55 Megan Abadom was involved in the interpretation of data and drafting of the manuscript.
56
57
58

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Aanand D. Naik was involved in the conception of the study and revision of the manuscript.

For peer review only

References

1. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. *N Engl J Med*. Jul 20 2017;377(3):305. doi:10.1056/NEJMc1706325
2. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. *Am J Hematol*. Jan 2010;85(1):77-8. doi:10.1002/ajh.21570
3. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. *N Engl J Med*. Jun 9 1994;330(23):1639-44. doi:10.1056/NEJM199406093302303
4. Saulsberry AC, Porter JS, Hankins JS. A program of transition to adult care for sickle cell disease. *Hematology Am Soc Hematol Educ Program*. Dec 6 2019;2019(1):496-504. doi:10.1182/hematology.2019000054
5. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. *N Engl J Med*. May 18 1995;332(20):1317-22. doi:10.1056/NEJM199505183322001
6. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. *JAMA*. Apr 2 2003;289(13):1645-51. doi:10.1001/jama.289.13.1645
7. Johnston EE, Adesina OO, Alvarez E, et al. Acute Care Utilization at End of Life in Sickle Cell Disease: Highlighting the Need for a Palliative Approach. *J Palliat Med*. Jan 2020;23(1):24-32. doi:10.1089/jpm.2018.0649
8. Levenson JL, McClish DK, Dahman BA, et al. Depression and anxiety in adults with sickle cell disease: the PiSCES project. *Psychosom Med*. Feb 2008;70(2):192-6. doi:10.1097/PSY.0b013e31815ff5c5
9. Adam SS, Flahiff CM, Kamble S, Telen MJ, Reed SD, De Castro LM. Depression, quality of life, and medical resource utilization in sickle cell disease. *Blood Adv*. Oct 24 2017;1(23):1983-1992. doi:10.1182/bloodadvances.2017006940
10. Laurence B, George D, Woods D. Association between elevated depressive symptoms and clinical disease severity in African-American adults with sickle cell disease. *J Natl Med Assoc*. Mar 2006;98(3):365-9.
11. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. *Blood Adv*. Jun 23 2020;4(12):2656-2701. doi:10.1182/bloodadvances.2020001851
12. Lee S, Vania DK, Bhor M, Revicki D, Abogunrin S, Sarri G. Patient-Reported Outcomes and Economic Burden of Adults with Sickle Cell Disease in the United States: A Systematic Review. *Int J Gen Med*. 2020;13:361-377. doi:10.2147/IJGM.S257340
13. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. *Am J Hematol*. Jun 2009;84(6):323-7. doi:10.1002/ajh.21408
14. Sepulveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: the World Health Organization's global perspective. *J Pain Symptom Manage*. Aug 2002;24(2):91-6. doi:10.1016/s0885-3924(02)00440-2
15. Casarett D, Pickard A, Bailey FA, et al. Do palliative consultations improve patient outcomes? *J Am Geriatr Soc*. Apr 2008;56(4):593-9. doi:10.1111/j.1532-5415.2007.01610.x
16. Gade G, Venohr I, Conner D, et al. Impact of an inpatient palliative care team: a randomized control trial. *J Palliat Med*. Mar 2008;11(2):180-90. doi:10.1089/jpm.2007.0055
17. Ajayi TA, Edmonds KP, Thornberry K, Atayee RA. Palliative Care Teams as Advocates for Adults with Sickle Cell Disease. *J Palliat Med*. Feb 2016;19(2):195-201. doi:10.1089/jpm.2015.0268
18. NIS Database Documentation. Accessed June 1, 2021, <https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp>

19. National Cancer Institute. Joinpoint trend analysis software. Accessed June 1, 2021, <https://surveillance.cancer.gov/joinpoint/>
20. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med*. Aug 19 2010;363(8):733-42. doi:10.1056/NEJMoa1000678
21. Osunkwo I, Andemariam B, Minniti CP, et al. Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY). *Am J Hematol*. Apr 1 2021;96(4):404-417. doi:10.1002/ajh.26063
22. Wen Y, Jiang C, Koncicki HM, et al. Trends and Racial Disparities of Palliative Care Use among Hospitalized Patients with ESKD on Dialysis. *J Am Soc Nephrol*. Sep 2019;30(9):1687-1696. doi:10.1681/ASN.2018121256
23. Lee K, Gani F, Canner JK, Johnston FM. Racial Disparities in Utilization of Palliative Care Among Patients Admitted With Advanced Solid Organ Malignancies. *Am J Hosp Palliat Care*. May 6 2020;1049909120922779. doi:10.1177/1049909120922779
24. Ornstein KA, Roth DL, Huang J, et al. Evaluation of Racial Disparities in Hospice Use and End-of-Life Treatment Intensity in the REGARDS Cohort. *JAMA Netw Open*. Aug 3 2020;3(8):e2014639. doi:10.1001/jamanetworkopen.2020.14639
25. Johnson KS, Kuchibhatla M, Tulsy JA. Racial differences in self-reported exposure to information about hospice care. *J Palliat Med*. Oct 2009;12(10):921-7. doi:10.1089/jpm.2009.0066
26. Cort MA. Cultural mistrust and use of hospice care: challenges and remedies. *J Palliat Med*. Feb 2004;7(1):63-71. doi:10.1089/109662104322737269
27. Mack JW, Paulk ME, Viswanath K, Prigerson HG. Racial disparities in the outcomes of communication on medical care received near death. *Arch Intern Med*. Sep 27 2010;170(17):1533-40. doi:10.1001/archinternmed.2010.322
28. Barnato AE, Anthony DL, Skinner J, Gallagher PM, Fisher ES. Racial and ethnic differences in preferences for end-of-life treatment. *J Gen Intern Med*. Jun 2009;24(6):695-701. doi:10.1007/s11606-009-0952-6
29. Johnson KS. Racial and ethnic disparities in palliative care. *J Palliat Med*. Nov 2013;16(11):1329-34. doi:10.1089/jpm.2013.9468
30. Saeed F, Hoerger M, Norton SA, Guancial E, Epstein RM, Duberstein PR. Preference for Palliative Care in Cancer Patients: Are Men and Women Alike? *J Pain Symptom Manage*. Jul 2018;56(1):1-6 e1. doi:10.1016/j.jpainsymman.2018.03.014
31. Gott M, Morgan T, Williams L. Gender and palliative care: a call to arms. *Palliat Care Soc Pract*. 2020;14:2632352420957997. doi:10.1177/2632352420957997
32. McClish DK, Levenson JL, Penberthy LT, et al. Gender differences in pain and healthcare utilization for adult sickle cell patients: The PiSCES Project. *J Womens Health (Larchmt)*. Mar 2006;15(2):146-54. doi:10.1089/jwh.2006.15.146
33. Patel AA, Walling AM, Ricks-Oddie J, May FP, Saab S, Wenger N. Palliative Care and Health Care Utilization for Patients With End-Stage Liver Disease at the End of Life. *Clin Gastroenterol Hepatol*. Oct 2017;15(10):1612-1619 e4. doi:10.1016/j.cgh.2017.01.030
34. Yu KG, Shen JJ, Kim PC, et al. Trends of Hospital Palliative Care Utilization and Its Associated Factors Among Patients With Systemic Lupus Erythematosus in the United States From 2005 to 2014. *Am J Hosp Palliat Care*. Mar 2020;37(3):164-171. doi:10.1177/1049909119891999
35. Lee L, Smith-Whitley K, Banks S, Puckrein G. Reducing Health Care Disparities in Sickle Cell Disease: A Review. *Public Health Rep*. Nov/Dec 2019;134(6):599-607. doi:10.1177/0033354919881438
36. Timbie JW, Kranz AM, Mahmud A, Damberg CL. Specialty care access for Medicaid enrollees in expansion states. *Am J Manag Care*. Mar 1 2019;25(3):e83-e87.

- 1
2
3 37. Fingar KR, Owens PL, Reid LD, Mistry KB, Barrett ML. Characteristics of Inpatient Hospital Stays
4 Involving Sickle Cell Disease, 2000-2016: Statistical Brief #251. *Healthcare Cost and Utilization Project*
5 *(HCUP) Statistical Briefs*. 2006.
6
7 38. Hua M, Li G, Clancy C, Morrison RS, Wunsch H. Validation of the V66.7 Code for Palliative Care
8 Consultation in a Single Academic Medical Center. *J Palliat Med*. Apr 2017;20(4):372-377.
9 doi:10.1089/jpm.2016.0363
10 39. Feder SL, Redeker NS, Jeon S, et al. Validation of the ICD-9 Diagnostic Code for Palliative Care in
11 Patients Hospitalized With Heart Failure Within the Veterans Health Administration. *Am J Hosp Palliat*
12 *Care*. Jul 2018;35(7):959-965. doi:10.1177/1049909117747519
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Patient characteristics among SCD-related hospitalizations and among those with SCD who received palliative care during their hospitalization

	Total N=307709982	SCD-related hospitalizations N=987555	Prevalence of SCD-related hospitalizations (per 1000 hospitalizations)	SCD-related hospitalizations receiving palliative care N=4442	Prevalence of palliative care use (per 1000 SCD hospitalizations)
Age Group					
18-39 years	75567499	733837	9.7	2824	3.8
40-59 years	78526326	214939	2.7	1160	5.4
60-79 years	101611492	35362	0.3	339	9.6
80+ years	52004665	3417	0.1	119	34.8
Race/Ethnicity					
NH-White	192567014	16962	0.1	214	12.6
NH-Black	41490748	857006	20.7	3773	4.4
Hispanic	29897432	32676	1.1	116	3.6
Others	17422072	23026	1.3	157	6.8
Missing	26332714	57883	2.2	181	3.1
Sex					
Male	125745784	427285	3.4	1921	4.5
Female	181778482	559845	3.1	2521	4.5
Missing	185716	424	2.3	—	—
Discharge Status					
Routine	202797074	853218	4.2	2619	3.1
Transfer	55186460	37409	0.7	447	11.9
Died	6740712	6327	0.9	685	108.3
DAMA	3847845	44520	11.6	69	1.5
Other	38933666	45507	1.2	622	13.7
Missing	204225	573	2.8	—	—
Zip code income quartile					
Lowest quartile	89460128	478674	5.4	2053	4.3
2nd quartile	78497949	219619	2.8	801	3.6
3rd quartile	71474969	163233	2.3	836	5.1
Highest quartile	61340502	100769	1.6	703	7.0
Missing	6936433	25259	3.6	48	1.9
Primary Payer					
Medicare	141357438	315777	2.2	1736	5.5
Medicaid	50563783	428967	8.5	1725	4.0
Private Insurance	88933878	170459	1.9	671	3.9
Self-Pay	26247689	70526	2.7	304	4.3
Missing	607194	1825	3.0	—	—
Hospital Characteristics					
Hospital Region					
Northeast	33888883	46282	1.4	1226	6.1
Midwest	107572349	234180	2.2	1014	5.4
South	164884575	701680	4.3	1820	3.6

West	1364173	5411	4.0	382	4.4
Hospital Bed Size					
Small	46455596	114366	2.5	331	2.9
Medium	81563430	258481	3.2	998	3.9
Large	178326782	609296	3.4	3108	5.1
Missing	1364173	5411	4.0	—	—
Hospital Location and Teaching Status					
Rural	33888883	46282	1.4	96	2.1
Urban non-teaching	107572349	234180	2.2	749	3.2
Urban teaching	164884575	701680	4.3	3591	5.1
Missing	1364173	5411	4.0	—	—

SCD-Sickle Cell Disease

NH-Non-Hispanic

DAMA-Discharged Against Medical Advice

Prevalence is the rate of the outcome (SCD or palliative care usage) among each patient characteristics

'—' represents cell values <10, which have been suppressed to preserve patient confidentiality, as per HCUP guidelines.

Table 2: Factors associated with palliative care use in SCD patients – overall and among those who died in-hospital

	Palliative care use in SCD hospitalizations	Palliative care use among SCD patients who died in-hospital
	OR(95% CI)	OR(95% CI)
Age Group		
18-39 years	reference	reference
40-59 years	0.98(0.81-1.18)	1.81(1.19-2.75)*
60-79 years	0.95(0.70-1.30)	1.13(0.60-2.12)
80+ years	2.34(1.41-3.88)*	2.29(0.79-6.64)
Race/Ethnicity		
NH-White	reference	reference
NH-Black	0.67(0.45-0.99)*	0.33(0.16-0.68)*
Hispanic	0.47(0.26-0.84)*	0.28(0.09-0.91)*
Others	0.83(0.49-1.39)	0.41(0.12-1.42)
Sex		
Male	reference	reference
Female	0.40(0.21-0.76)*	1.45(1.00-2.11)
Discharge Status		
Routine	reference	reference
Transfer	3.71(2.73-5.03)*	
Died	39.26(30.83-49.98)*	—
DAMA	0.48(0.28-0.84)*	—
Other	4.14(3.20-5.35)*	—
Zip code income quartile		
Lowest quartile	reference	reference
2nd quartile	0.89(0.71-1.11)	0.69(0.42-1.14)
3rd quartile	1.24(0.85-1.80)	0.48(0.25-0.91)*
Highest quartile	1.58(1.02-2.45)*	1.46(0.79-2.71)
Primary Payer		
Medicare	reference	reference
Medicaid	0.40(0.21-0.78)*	0.72(0.21-2.48)
Private Insurance	1.30(1.02-1.65)*	1.03(0.59-1.79)
Self-Pay	1.22(0.93-1.59)	1.12(0.64-1.99)
Hospital Characteristics		
Hospital Region		
Northeast	reference	reference
Midwest	1.00(0.57-1.75)	1.18(0.57-2.46)
South	0.69(0.42-1.11)	1.47(0.78-2.78)
West	0.72(0.40-1.31)	1.63(0.77-3.41)
Hospital Bed Size		
Small	reference	reference
Medium	1.47(1.02-2.12)*	1.18(0.57-2.44)
Large	1.91(1.30-2.82)*	1.52(0.78-2.96)
Hospital Location and Teaching Status		
Urban teaching	reference	reference
Rural	0.47(0.28-0.79)*	0.75(0.33-1.73)
Urban non-teaching	0.61(0.47-0.80)*	0.63(0.40-0.99)

1
2
3 SCD-Sickle Cell Disease
4 NH-Non-Hispanic
5 DAMA-Discharged Against Medical Advice
6 OR- odds ratio, CI- confidence interval
7 '—' represents the absence of variable in the model
8
9

10 **Figure legend/caption**

11 Figure 1: Temporal trends in the rates of palliative care use represented as average annual
12 percentage change (AAPC). ‘*’ represents statistically significant findings ($p < 0.05$). Rate of
13 inpatient palliative care service usage increased at average of 9.2% per year (95% CI, 5.6-12.9)
14 for all SCD-related hospitalizations and 10.7% (95% CI, 3.4-18.5) for terminal hospitalizations.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5,6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7,8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7,8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7,8
Bias	9	Describe any efforts to address potential sources of bias	Not applicable
Study size	10	Explain how the study size was arrived at	Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Not applicable
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8,9
		(b) Describe any methods used to examine subgroups and interactions	Not applicable
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	7
		(e) Describe any sensitivity analyses	Not applicable
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	Not applicable

Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	22, 23
Outcome data	15*	Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11,12
		(b) Report category boundaries when continuous variables were categorized	Not applicable
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not applicable
Discussion			
Key results	18	Summarise key results with reference to study objectives	13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15,16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13,14,15
Generalisability	21	Discuss the generalisability (external validity) of the study results	16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057361.R2
Article Type:	Original research
Date Submitted by the Author:	16-May-2022
Complete List of Authors:	Nwogu-Onyemkpa, Eberechi; Baylor College of Medicine, Department of Medicine, Center of Excellence in Health Equity, Training and Research; Baylor College of Medicine, Section of Geriatrics and Palliative Medicine Dongarwar, Deepa; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Salihu, HM; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Akpati, Lois; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Marroquin, Maricarmen; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Abadom, Megan; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Naik, Aanand; UTHealth School of Public Health, Management, Policy and Community Health; Michael E DeBakey VA Medical Center, Houston Center for Innovations in Quality, Effectiveness, and Safety
Primary Subject Heading:	Palliative care
Secondary Subject Heading:	Haematology (incl blood transfusion)
Keywords:	Adult palliative care < PALLIATIVE CARE, HAEMATOLOGY, Anaemia < HAEMATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

Title: Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

Eberechi Nwogu-Onyemkpa, MD^{1,2}, Deepa Dongarwar, MS¹, Hamisu M. Salihu, MD, PhD¹, Lois Akpati, BS¹, Maricarmen Marroquin, BS¹, Megan Abadom, BS¹, Aanand D. Naik, MD^{3,4}

Affiliations: ¹Baylor College of Medicine Center of Excellence in Health Equity, Training and Research, Houston, Texas

²Department of Medicine, Section of Geriatrics and Palliative Medicine, Baylor College of Medicine, Houston, Texas

³UTHealth Consortium on Aging; and Department of Management, Policy and Community Health, UT School of Public Health, Houston, Texas

⁴Houston Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas

28 Word count: 3,116

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Corresponding Author:

Eberechi Nwogu-Onyemkpa

eberechi.nwogu-onyemkpa@bcm.edu

6501 Fannin St. NC 100, Houston, Texas 77030

1
2
3
4
5
6
7 **Abstract:**
8
9

10 **Objective:** Sickle cell disease (SCD) is a highly morbid condition notable for recurrent
11 hospitalizations due to vaso-occlusive crises and complications of end organ damage. Little is
12 known about the use of inpatient palliative care services in adult patients with SCD. This study
13 aims to evaluate inpatient palliative care use during SCD related hospitalizations overall and
14 during terminal hospitalizations. We hypothesize that use of palliative care is low in SCD
15 hospitalizations.
16
17
18
19
20
21
22
23

24
25 **Design:** A retrospective cross-sectional study utilizing data from the National Inpatient Sample
26 (NIS) from 2008-2017 was conducted.
27
28
29

30
31 **Setting:** US hospitals from 47 states and the District of Columbia.
32
33

34 **Participants:** Patients >18 years old hospitalized with a primary or secondary ICD-9-CM or
35 ICD-10-CM diagnosis of SCD were included.
36
37
38
39

40 **Primary and secondary outcome measures:** Palliative care service use (documented by ICD-9-
41 CM and ICD-10-CM diagnosis codes V66.7 and Z51.5).
42
43
44

45 **Results:** 987,555 SCD-related hospitalizations were identified, of which 4442 (0.45%) received
46 palliative care service. Palliative care service use increased at a rate of 9.2% per year (CI, 5.6-
47 12.9). NH-Black and Hispanic patients were 33% and 53% less likely to have palliative care
48 services compared to NH-White patients (OR 0.67; CI 0.45-0.99 and OR 0.47; CI, 0.26-0.84).
49
50
51
52
53
54
55
56
57
58
59
60
Female patients (OR 0.40; CI, 0.21-0.76), Medicaid use (OR 0.40; CI, 0.21-0.78), rural (OR

1
2
3 0.47; CI 0.28-0.79) and urban non-teaching hospitals (OR 0.61; CI 0.47-0.80) each had a lower
4
5 likelihood of palliative care services use.
6
7

8
9 **Conclusion:** Use of palliative care during SCD-related hospitalizations is increasing but remains
10
11 low. Disparities associated with race and gender exist for use of palliative care services during
12
13 SCD related hospitalization. Further studies are needed to guide evidence-based palliative care
14
15 interventions for more comprehensive and equitable care of adult patients with SCD.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- Our study is the first of its kind to investigate palliative care use among SCD patients using a national database.
- ICD-9-CM and ICD-10-CM codes for palliative care are not specific to palliative care provided by a palliative care specialist as these codes also encompass patients who are in comfort care status.
- Our study investigated inpatient palliative care use and hence, our findings cannot be extrapolated to outpatient setting where patients with SCD patient receive most of their care.

Introduction:

Sickle cell disease (SCD) is a group of inherited red blood cell disorders in which abnormality in Hemoglobin (Hb) beta gene results in abnormal shape and sickling of red blood cells under stress. Physiologic manifestations of the illness arise from end organ ischemia, including acute pain from vaso-occlusive crises, cerebrovascular accident, acute chest syndrome, pulmonary hypertension, heart failure, renal failure, severe anemia, and recurrent infections.¹ Approximately 100,000 Americans predominantly of African (90%), Middle Eastern, and Mediterranean descent are affected by SCD.² Historically, SCD was a childhood disease – life expectancy for those with the disease was 20 years in 1970. Currently, life expectancy with SCD extends into adulthood (42-48 years) but remains significantly lower than the general population, especially for sickle cell anemia—the most severe form of SCD.³ As an increasing number of people with SCD survive into adulthood, there is a rising need for effective transitions to adult medicine involving multidisciplinary care teams.⁴

SCD is a highly morbid condition. Recurrent hospitalization is common in SCD due to vaso-occlusive crises and complications of end organ damage.^{5 6} During their last year of life, people with SCD were hospitalized for an average of forty-two days over five admissions.⁷ Hospital admissions and ED visits increase sharply a month before death and most patients with SCD die in the hospital (63%) or emergency department (15%).⁷ Patients with SCD experience increased rates of depression and anxiety,^{8 9 10} chronic pain,¹¹ and decreased health-related quality of life.¹² Increased healthcare use¹³ and symptom burden are salient opportunities for palliative care intervention in this patient population. Palliative care provides holistic care for patients with serious chronic illnesses using a multidisciplinary team approach.¹⁴ Palliative care has been

1
2
3 shown to increase patient's quality of life and decrease health care costs^{15 16} but the impact of
4
5 palliative care on SCD is not well characterized.¹⁷
6
7

8 Furthermore, little is known about the use of *inpatient* palliative care services in adult patients
9
10 with SCD. To address this gap, we used national data to evaluate inpatient palliative care use
11
12 during SCD related hospitalizations overall and during terminal hospitalizations (hospitalizations
13
14 that resulted in patients' death in-hospital regardless of cause of death). We identified patient and
15
16 hospital characteristics associated with use of hospital-based palliative care services in SCD. We
17
18 hypothesize that use of palliative care is low in SCD hospitalizations.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods:

Data Source

Data from the 2008 to 2017 National Inpatient Sample (NIS), the largest all-payer, nationally representative inpatient database in the United States (US) was used. The NIS is part of a group of databases developed by the Healthcare Utilization Project (HCUP) and sponsored by the Agency for Healthcare Research and Quality (AHRQ).¹⁸ This public database contains longitudinal data from a stratified sample of all discharges from US hospitals from 47 states and the District of Columbia, excluding rehabilitation and long-term acute care hospitals, thereby estimating about a 20% sample of all hospital discharges. When weighted, each year, NIS contains data from about 35 million hospitalizations.

Study Population and Variables

The analysis was restricted to hospitalizations in adults aged 18 years and above. Diagnoses and procedures are coded using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes till the 3rd quarter of 2015, after which HCUP transitioned to ICD-10-CM format. To identify the hospitalizations of interest, we first scanned the diagnosis codes (the principal diagnosis and up to 29 secondary diagnoses) in each patient's discharge record for an indication of SCD (ICD-9-CM - 282.41, 282.42, 282.61, 282.62, 282.63, 282.64, 282.60, 282.68, 282.69; ICD-10-CM - D57.4x, D57.0x, D57.2x, D57.1x, D57.8x). The study's primary outcome was palliative care use which was identified using ICD-9-CM diagnosis code V66.7 and ICD-10-CM diagnosis code Z51.5. The ICD-9-CM and ICD-10-CM palliative care codes capture hospital encounters by a palliative care specialist or service, patients admitted

1
2
3 for palliative care, and patients on comfort measures only status. There were no changes in the
4
5 criteria for palliative care code with the transition from ICD-9-CM to ICD-10-CM. Covariates
6
7 included in the study were socio-demographics for the patient which consisted of patients' age,
8
9 race/ethnicity – categorized as Non-Hispanic (NH)-White, NH-Black, Hispanic and NH-Others,
10
11 sex, insurance type – Medicare, Medicaid, private insurance, self-pay and others, median
12
13 household income based on zipcodes; and hospital characteristics such as hospital location,
14
15 hospital type (urban vs. rural and teaching vs. non-teaching), and hospital bed size.
16
17
18
19

20 Statistical Analysis

21
22
23
24 Since the NIS data was de-identified and publicly available, the study was approved as exempt
25
26 by the Institutional Review Board (IRB) of Baylor College of Medicine. All statistical tests were
27
28 two-tailed with the type-I error of 5% and were conducted using R version 3.5.1 (University of
29
30 Auckland, Auckland, New Zealand) and R Studio Version 1.1.423 (Boston, MA) and Joinpoint
31
32 Regression Program, version 4.7.0.0 (National Cancer Institute).
33
34
35

36
37 Temporal trends analyses were performed using Joinpoint regression technique, which enables
38
39 examination of the trend of an outcome (in this case, palliative care use) over the study period.¹⁹
40

41 The results are represented in the form of average annual percentage change (AAPC) and its
42
43 95% confidence interval (CI). We scrutinized the temporal trends in the rates of palliative care
44
45 use among SCD patients overall, and among those who died in-hospital. Next, we examined the
46
47 socio-demographic and hospitalization characteristics of patients with SCD and those with SCD
48
49 who received palliative care during their hospitalization. Prevalence rates of SCD and palliative
50
51 care use among SCD hospitalizations were calculated, stratified by patients' race/ethnicity.
52
53

54
55 Furthermore, after excluding records with missing values in model variables, we conducted
56
57
58
59

1
2
3 adjusted survey logistic regression models to examine the patient socio-demographic and
4
5 hospitalization characteristics (exposure variables) associated with palliative care use (outcome
6
7 variable) among all SCD hospitalizations and among those which resulted in patients' death in-
8
9 hospital. All the patient demographic and hospital characteristics were loaded into the
10
11 association models to obtain adjusted odds ratio and 95% confidence intervals.
12
13
14
15

16 **Patient and public involvement**

17
18 Patients were not involved in this retrospective analysis of an anonymized national inpatient
19
20 database.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results:***Trends in the rate of palliative care use in SCD-related hospitalizations***

During the study period of 1 January 2008 to 31 December 2017, the NIS contained 987,555 SCD-related hospitalizations of which 6,327 (0.64%) were terminal admissions. There were 4442 (0.45%) SCD-related hospitalizations that received palliative care service. Figure 1 shows temporal trends in palliative care use. The rate of inpatient palliative care service use increased at an average of 9.2% per year (95% CI, 5.6-12.9) for all SCD-related hospitalizations – from 2.86 per 1000 hospitalizations in 2008 to 6.32 per 1000 hospitalizations in 2017; and an average of 10.7% (95% CI, 3.4-18.5) for terminal hospitalizations – 6.34 per 1000 hospitalizations in 2008 to 15.82 per 1000 hospitalizations in 2017.

Patient characteristics – SCD hospitalizations with palliative care use

Table 1 shows patient characteristics for SCD related hospitalizations and patients who received palliative care services. The prevalence of SCD-related hospitalization was highest among the 18-39 age group (9.7 per 1000 SCD hospitalizations) and decreased with increasing age. Conversely, the prevalence of inpatient palliative care use was highest in the oldest age group (34.8 per 1000 SCD hospitalization) and lowest in the 18-39 age group (3.8 per 1000 SCD hospitalizations). The prevalence of SCD-related hospitalization was highest among NH-Blacks (20.7 per 1000 SCD hospitalizations) and lowest in NH-Whites (0.1 per 1000 SCD hospitalizations) while the prevalence of inpatient palliative care services was highest in NH-Whites (12.6 per 1000 SCD hospitalizations) and lowest in Hispanics (3.6 per 1000 SCD hospitalizations).

Regional and hospital characteristics – SCD hospitalizations with palliative care use

1
2
3 SCD hospitalization was lowest in the Northeast (1.4 per 1000 SCD hospitalizations) but the
4 prevalence of inpatient palliative care service was highest in this region (6.1 per 1000 SCD
5 hospitalizations). Conversely the South region had the highest prevalence of SCD hospitalization
6 (4.3 per 1000 SCD hospitalizations) but the lowest use of inpatient palliative care services (3.6
7 per 1000 SCD hospitalizations). Large and urban teaching hospitals had the highest prevalence
8 of SCD hospitalization (3.4 and 4.3 per 1000 hospitalizations, respectively) and highest level of
9 inpatient palliative care service use (5.1 and 5.1 per 1000 SCD hospitalizations, respectively).

20 ***Factors associated with inpatient palliative care use in SCD***

21
22 Table 2 shows factors associated with inpatient palliative care use in SCD hospitalizations.
23
24 During terminal hospitalizations patients between 40-59 years were more likely to receive
25 palliative care services than patients 18-39 years old (odds ratio [OR], 1.81, 95% confidence
26 interval [CI], 1.19-2.75). NH-Black and Hispanic patients were less likely to receive inpatient
27 palliative care services compared to NH-White (OR, 0.67; 95% CI, 0.45-0.99 and OR, 0.47; 95%
28 CI, 0.26-0.84, respectively). Likewise, during terminal admissions use of palliative care services
29 was less likely among NH-Black and Hispanic patients, respectively when compared to NH-
30 White (OR, 0.33; 95% CI, 0.16-0.68 and OR, 0.28; 95% CI, 0.09-0.91, respectively). Female
31 patients were less likely to receive palliative care services than male patients (OR, 0.40; 95% CI,
32 0.21-0.76). Compared to routine discharges, hospitalizations resulting in death and transfer to
33 another health care facility were associated with increased odds of use of inpatient palliative care
34 services (OR, 39.36; 95% CI, 30.83-49.98, and OR, 3.71; 95% CI, 2.73-5.03, respectively) while
35 discharge against medical advice (DAMA) was associated with decreased odds of use of
36 inpatient palliative care services (OR, 0.48; 95% CI 0.28-0.84).

1
2
3 Patients living in zip codes in the highest income quartile were more likely to receive inpatient
4 palliative care services (OR, 1.58; 95% CI 1.02-2.45) than those in the lowest quartile.

5
6
7 Compared to Medicare patients, those with Medicaid had lesser odds (OR, 0.40; 95% CI, 0.21-
8 0.78), while patients with private insurance had higher odds (OR, 1.30; 95% CI, 0.93-1.59) of
9 receiving palliative care services. During terminal admissions, there were no significant
10 differences in palliative care use across different payors.
11
12
13
14
15
16
17
18
19

20 Patients admitted to medium or large hospitals were more likely (OR, 1.47; 95% CI, 1.02-2.12
21 and OR, 1.91; 95% CI, 1.30-2.82, respectively) to receive palliative care services than patients in
22 small hospitals while patients admitted to rural or urban non-teaching hospitals were less likely
23 to receive palliative care services than those in urban teaching hospitals (OR, 0.47; 95% CI 0.28-
24 0.79 and OR, 0.61; 95% CI 0.47-0.80, respectively).
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion:

In this study of national trends, we found overall low use of palliative care services during SCD-related hospitalizations. Palliative care use was more likely among patients who were NH-White male, in the highest income quartile, with private insurance, and who received care in large or urban academic hospitals. NH-Black and Hispanic patients were less likely to receive palliative care services especially during terminal hospitalizations.

While early palliative care has gained acceptance in cancer care,²⁰ its adoption in other serious life limiting conditions such as congestive heart failure, chronic kidney disease, and SCD lags. SCD has traditionally been viewed as a childhood disease as most patients did not survive to adulthood in the past. Currently, most patients with SCD survive to adulthood.³ Furthermore, some patients with SCD experience complications and end organ damage from their disease resulting in a shortened life expectancy than the general population. Our study found a higher prevalence of palliative care service use in terminal admissions when compared to admissions with routine discharge or transfer to another level of care. This highlights an opportunity for palliative care involvement earlier in the disease course in SCD, facilitating more holistic care of patients. Earlier initiation of palliative care grants patients psychosocial support and symptom management from an interdisciplinary team,²¹ as well as honest discussions regarding goals of care and patient's preference for end of life.

Our study showed most SCD-related hospitalizations and palliative care service use were in the NH-Black group. However, further analysis accounting for covariates revealed that NH-Black patients were significantly less likely to receive palliative care during hospitalization compared to NH-white patients. Notably, race/ethnicity was the only factor associated with palliative care

1
2
3 use in both SCD and terminal hospitalizations. Other studies have shown racial disparities in the
4 use of palliative care services in other chronic diseases.^{22,23} Furthermore, studies have shown that
5 black patients are less likely to use hospice services and more likely to receive intensive life-
6 sustaining procedures at end of life compared to white patients.²⁴ Factors identified to drive this
7 racial disparity in hospice use include knowledge deficits,²⁵ mistrust of the health care system,²⁶
8 miscommunication and misunderstanding of treatment options,²⁷ and preference for more
9 aggressive.²⁸ Similar studies are lacking to elucidate factors implicated in the racial difference in
10 non-hospice palliative care use across all life limiting diseases.²⁹ Palliative care has a strong
11 perceived association with hospice with many patients and families unable to differentiate
12 between the two. Therefore, the above factors identified above relating to hospice use are likely
13 are likely to also play a role in racial differences observed in palliative care use in patients with
14 chronic conditions such as SCD. Further studies are needed to investigate patient and system
15 factors associated with racial differences in palliative care use in SCD.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Gender differences in the use of inpatient palliative care services were found. Although male and
35 female patients had a similar prevalence of SCD-related hospitalization, female patients were
36 60% less likely to receive palliative care services. This finding is contrary to that of other studies
37 which show that women are more receptive to palliative care than men.³⁰ Pain is the most
38 prominent feature of SCD and hence it is plausible that inpatient palliative care services in SCD
39 hospitalizations primarily involve pain management. Studies have shown that although most
40 chronic pain conditions are more prevalent in women than men, and women report greater pain
41 than men after invasive procedures, women receive less analgesia and are more likely to have
42 their pain attributed to psychological causes.³¹ It is possible that palliative care consultants are
43 more frequently involved for specialist level pain management for male than female patients
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 accounting for the gender difference observed in our study. This finding requires further
4 investigation as the study by McClish et al. demonstrates that men and women with SCD report
5 similar pain experiences.³²
6
7

8
9
10 We also found socioeconomic differences in the use of palliative care in SCD similar to other
11 diseases.^{23,33,34} Patients with zip codes in the highest income quartile and those with private
12 insurance were more likely to receive palliative care, while patients with Medicaid were less
13 likely to receive palliative care services. Insurance dictates patient's access to specialty care with
14 patients on Medicaid reporting more challenge than those with private insurance accessing
15 certain specialty care particularly in the outpatient setting.^{35,36}
16
17
18
19
20
21
22
23

24 Regional differences were detected in our study. The South region had the highest number of
25 SCD hospitalizations but the lowest prevalence of palliative care use. This finding is notable as
26 two of the three states (Florida, Texas, and New York) with the highest population of SCD
27 patients are in the South. Hospital characteristics were also predictive of palliative care use with
28 medium, large and urban teaching hospitals associated with greater use of palliative care in SCD
29 similar to findings from other studies.^{33 22 34} While many sickle cell patients use larger, urban
30 hospitals for their care,³⁷ this study highlights the need for improvement in access to palliative
31 care services across all settings in the US, particularly in small and rural hospitals.
32
33
34
35
36
37
38
39
40
41
42

43 To our knowledge, our study is the first of its kind to investigate palliative care use among SCD
44 patients using a national data base. Limitations exist in our study one of which is the validity of
45 the ICD-9 and ICD-10 codes for identification of palliative care consultations. Investigators have
46 sought to validate these codes however these studies utilize data from a single institution³⁸ or
47 from the VA system.³⁹ Furthermore, the ICD-9 and ICD-10 codes for palliative care are not
48 specific to palliative care provided by a palliative care specialist as these codes also encompass
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 patients who are in comfort care status.⁴⁰ Not all patients in comfort care are managed by a
4
5 palliative care specialist and as such it is difficult to delineate which hospitalizations were indeed
6
7 associated with the involvement of a palliative care specialist. In addition, our dataset does not
8
9 allow us to elucidate the nature of palliative care interventions provided during admissions hence
10
11 it is unclear if these interventions were for symptom management, goals of care discussion,
12
13 counseling and support, or transition to comfort care. Given utilization of aggregate data in
14
15 which a hospitalization is considered a single event, we are unable to identify the number of
16
17 patients who benefited from palliative care services as multiple admissions could be associated
18
19 with one patient. As such, we suspect that our study overestimates the prevalence of palliative
20
21 care use in SCD. Lastly, our study investigated inpatient palliative care use and hence, our
22
23 findings cannot be extrapolated to outpatient settings where patients with SCD patient receive
24
25 most of their care.
26
27
28
29

30
31 SCD related morbidity and mortality have a significant impact on patient self-reported quality of
32
33 life outcomes and healthcare utilization and cost. Early palliative care might guide patients'
34
35 treatment decisions and mitigate initiation of interventions that are not in line with a patients'
36
37 wishes at the end of life. Early palliative care also has the potential to improve symptom
38
39 management and consequently improve quality of life for individuals with SCD. Studies
40
41 exploring barriers and facilitators to early palliative care at the provider (SCD providers,
42
43 palliative care specialists), patient, and system levels do not exist and are needed for future
44
45 recommendation for PC interventions in this population. Racial disparity in the use of palliative
46
47 care by SCD patients should be investigated with studies assessing knowledge of palliative care
48
49 and barriers to palliative care use by SCD patients. Furthermore, studies addressing system
50
51
52
53
54
55
56
57
58
59
60

1
2
3 barriers to palliative care use among minority patients are needed as the implication spans across
4
5 other life limiting illnesses.
6
7

8 **Acknowledgements**

9
10
11 **Conflict of Interest Disclosures:** Authors *without* conflicts of interest, including relevant
12
13 financial interests, activities, relationships, and affiliations.
14
15

16
17 **Funding/Support:** Research funding support was provided by the US Department of Health and
18
19 Human Services and Health Resources and Services Administration for Baylor College of
20
21 Medicine Center of Excellence in Health Equity, Training, and Research (Grant No:
22
23 D34HP31024). Additional support is provided to Dr. Naik from the Houston VA HSR&D Center
24
25 for Innovations in Quality, Effectiveness, and Safety (CIN 13-413).
26
27
28
29

30 **Authorship Contribution:**

31
32
33 Eberechi Nwogu-Onyemkpa was involved in the conception of the study, interpretation of data,
34
35 drafting, and revision of the manuscript.
36
37

38
39 Deepa Dongarwar was involved in the conception of the study, analysis of the data, drafting, and
40
41 revision of the manuscript.
42
43

44 Hamisu Salihu was involved in the conception of the study and revision of the manuscript.
45
46

47 Chioma Akpati was involved in the interpretation of data and drafting of the manuscript.
48
49

50 Maricarmen Marroquin was involved in the interpretation of data, drafting and revision of the
51
52 manuscript.
53
54

55 Megan Abadom was involved in the interpretation of data and drafting of the manuscript.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Aanand D. Naik was involved in the conception of the study and revision of the manuscript.

For peer review only

References

1. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. *N Engl J Med*. Jul 20 2017;377(3):305. doi:10.1056/NEJMc1706325
2. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. *Am J Hematol*. Jan 2010;85(1):77-8. doi:10.1002/ajh.21570
3. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. *N Engl J Med*. Jun 9 1994;330(23):1639-44. doi:10.1056/NEJM199406093302303
4. Saulsberry AC, Porter JS, Hankins JS. A program of transition to adult care for sickle cell disease. *Hematology Am Soc Hematol Educ Program*. Dec 6 2019;2019(1):496-504. doi:10.1182/hematology.2019000054
5. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. *N Engl J Med*. May 18 1995;332(20):1317-22. doi:10.1056/NEJM199505183322001
6. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. *JAMA*. Apr 2 2003;289(13):1645-51. doi:10.1001/jama.289.13.1645
7. Johnston EE, Adesina OO, Alvarez E, et al. Acute Care Utilization at End of Life in Sickle Cell Disease: Highlighting the Need for a Palliative Approach. *J Palliat Med*. Jan 2020;23(1):24-32. doi:10.1089/jpm.2018.0649
8. Levenson JL, McClish DK, Dahman BA, et al. Depression and anxiety in adults with sickle cell disease: the PiSCES project. *Psychosom Med*. Feb 2008;70(2):192-6. doi:10.1097/PSY.0b013e31815ff5c5
9. Adam SS, Flahiff CM, Kamble S, Telen MJ, Reed SD, De Castro LM. Depression, quality of life, and medical resource utilization in sickle cell disease. *Blood Adv*. Oct 24 2017;1(23):1983-1992. doi:10.1182/bloodadvances.2017006940
10. Laurence B, George D, Woods D. Association between elevated depressive symptoms and clinical disease severity in African-American adults with sickle cell disease. *J Natl Med Assoc*. Mar 2006;98(3):365-9.
11. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. *Blood Adv*. Jun 23 2020;4(12):2656-2701. doi:10.1182/bloodadvances.2020001851
12. Lee S, Vania DK, Bhor M, Revicki D, Abogunrin S, Sarri G. Patient-Reported Outcomes and Economic Burden of Adults with Sickle Cell Disease in the United States: A Systematic Review. *Int J Gen Med*. 2020;13:361-377. doi:10.2147/IJGM.S257340
13. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. *Am J Hematol*. Jun 2009;84(6):323-7. doi:10.1002/ajh.21408
14. Sepulveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: the World Health Organization's global perspective. *J Pain Symptom Manage*. Aug 2002;24(2):91-6. doi:10.1016/s0885-3924(02)00440-2
15. Casarett D, Pickard A, Bailey FA, et al. Do palliative consultations improve patient outcomes? *J Am Geriatr Soc*. Apr 2008;56(4):593-9. doi:10.1111/j.1532-5415.2007.01610.x
16. Gade G, Venohr I, Conner D, et al. Impact of an inpatient palliative care team: a randomized control trial. *J Palliat Med*. Mar 2008;11(2):180-90. doi:10.1089/jpm.2007.0055
17. Ajayi TA, Edmonds KP, Thornberry K, Atayee RA. Palliative Care Teams as Advocates for Adults with Sickle Cell Disease. *J Palliat Med*. Feb 2016;19(2):195-201. doi:10.1089/jpm.2015.0268
18. NIS Database Documentation. Accessed June 1, 2021, <https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp>

19. National Cancer Institute. Joinpoint trend analysis software. Accessed June 1, 2021, <https://surveillance.cancer.gov/joinpoint/>
20. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med*. Aug 19 2010;363(8):733-42. doi:10.1056/NEJMoa1000678
21. Osunkwo I, Andemariam B, Minniti CP, et al. Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY). *Am J Hematol*. Apr 1 2021;96(4):404-417. doi:10.1002/ajh.26063
22. Wen Y, Jiang C, Koncicki HM, et al. Trends and Racial Disparities of Palliative Care Use among Hospitalized Patients with ESKD on Dialysis. *J Am Soc Nephrol*. Sep 2019;30(9):1687-1696. doi:10.1681/ASN.2018121256
23. Lee K, Gani F, Canner JK, Johnston FM. Racial Disparities in Utilization of Palliative Care Among Patients Admitted With Advanced Solid Organ Malignancies. *Am J Hosp Palliat Care*. May 6 2020;1049909120922779. doi:10.1177/1049909120922779
24. Ornstein KA, Roth DL, Huang J, et al. Evaluation of Racial Disparities in Hospice Use and End-of-Life Treatment Intensity in the REGARDS Cohort. *JAMA Netw Open*. Aug 3 2020;3(8):e2014639. doi:10.1001/jamanetworkopen.2020.14639
25. Johnson KS, Kuchibhatla M, Tulsy JA. Racial differences in self-reported exposure to information about hospice care. *J Palliat Med*. Oct 2009;12(10):921-7. doi:10.1089/jpm.2009.0066
26. Cort MA. Cultural mistrust and use of hospice care: challenges and remedies. *J Palliat Med*. Feb 2004;7(1):63-71. doi:10.1089/109662104322737269
27. Mack JW, Paulk ME, Viswanath K, Prigerson HG. Racial disparities in the outcomes of communication on medical care received near death. *Arch Intern Med*. Sep 27 2010;170(17):1533-40. doi:10.1001/archinternmed.2010.322
28. Barnato AE, Anthony DL, Skinner J, Gallagher PM, Fisher ES. Racial and ethnic differences in preferences for end-of-life treatment. *J Gen Intern Med*. Jun 2009;24(6):695-701. doi:10.1007/s11606-009-0952-6
29. Johnson KS. Racial and ethnic disparities in palliative care. *J Palliat Med*. Nov 2013;16(11):1329-34. doi:10.1089/jpm.2013.9468
30. Saeed F, Hoerger M, Norton SA, Guancial E, Epstein RM, Duberstein PR. Preference for Palliative Care in Cancer Patients: Are Men and Women Alike? *J Pain Symptom Manage*. Jul 2018;56(1):1-6 e1. doi:10.1016/j.jpainsymman.2018.03.014
31. Gott M, Morgan T, Williams L. Gender and palliative care: a call to arms. *Palliat Care Soc Pract*. 2020;14:2632352420957997. doi:10.1177/2632352420957997
32. McClish DK, Levenson JL, Penberthy LT, et al. Gender differences in pain and healthcare utilization for adult sickle cell patients: The PiSCES Project. *J Womens Health (Larchmt)*. Mar 2006;15(2):146-54. doi:10.1089/jwh.2006.15.146
33. Patel AA, Walling AM, Ricks-Oddie J, May FP, Saab S, Wenger N. Palliative Care and Health Care Utilization for Patients With End-Stage Liver Disease at the End of Life. *Clin Gastroenterol Hepatol*. Oct 2017;15(10):1612-1619 e4. doi:10.1016/j.cgh.2017.01.030
34. Yu KG, Shen JJ, Kim PC, et al. Trends of Hospital Palliative Care Utilization and Its Associated Factors Among Patients With Systemic Lupus Erythematosus in the United States From 2005 to 2014. *Am J Hosp Palliat Care*. Mar 2020;37(3):164-171. doi:10.1177/1049909119891999
35. Lee L, Smith-Whitley K, Banks S, Puckrein G. Reducing Health Care Disparities in Sickle Cell Disease: A Review. *Public Health Rep*. Nov/Dec 2019;134(6):599-607. doi:10.1177/0033354919881438
36. Timbie JW, Kranz AM, Mahmud A, Damberg CL. Specialty care access for Medicaid enrollees in expansion states. *Am J Manag Care*. Mar 1 2019;25(3):e83-e87.

- 1
2
3 37. Fingar KR, Owens PL, Reid LD, Mistry KB, Barrett ML. Characteristics of Inpatient Hospital Stays
4 Involving Sickle Cell Disease, 2000-2016: Statistical Brief #251. *Healthcare Cost and Utilization Project*
5 *(HCUP) Statistical Briefs*. 2006.
6
7 38. Hua M, Li G, Clancy C, Morrison RS, Wunsch H. Validation of the V66.7 Code for Palliative Care
8 Consultation in a Single Academic Medical Center. *J Palliat Med*. Apr 2017;20(4):372-377.
9 doi:10.1089/jpm.2016.0363
10
11 39. Feder SL, Redeker NS, Jeon S, et al. Validation of the ICD-9 Diagnostic Code for Palliative Care in
12 Patients Hospitalized With Heart Failure Within the Veterans Health Administration. *Am J Hosp Palliat*
13 *Care*. Jul 2018;35(7):959-965. doi:10.1177/1049909117747519
14
15 40. Stubbs JM, Assareh H, Achat HM, Greenaway S, Muruganatham P. Specialist Palliative Care
16 Activity at an Acute Care Tertiary Hospital and Its Representation in Administrative Data. *Am J Hosp*
17 *Palliat Care*. Mar 2021;38(3):216-222. doi:10.1177/1049909120939861
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Patient characteristics among SCD-related hospitalizations and among those with SCD who received palliative care during their hospitalization

	Total N=307709982	SCD-related hospitalizations N=987555	Prevalence of SCD-related hospitalizations (per 1000 hospitalizations)	SCD-related hospitalizations receiving palliative care N=4442	Prevalence of palliative care use (per 1000 SCD hospitalizations)
Age Group					
18-39 years	75567499	733837	9.7	2824	3.8
40-59 years	78526326	214939	2.7	1160	5.4
60-79 years	101611492	35362	0.3	339	9.6
80+ years	52004665	3417	0.1	119	34.8
Race/Ethnicity					
NH-White	192567014	16962	0.1	214	12.6
NH-Black	41490748	857006	20.7	3773	4.4
Hispanic	29897432	32676	1.1	116	3.6
Others	17422072	23026	1.3	157	6.8
Missing	26332714	57883	2.2	181	3.1
Sex					
Male	125745784	427285	3.4	1921	4.5
Female	181778482	559845	3.1	2521	4.5
Missing	185716	424	2.3	—	—
Discharge Status					
Routine	202797074	853218	4.2	2619	3.1
Transfer	55186460	37409	0.7	447	11.9
Died	6740712	6327	0.9	685	108.3
DAMA	3847845	44520	11.6	69	1.5
Other	38933666	45507	1.2	622	13.7
Missing	204225	573	2.8	—	—
Zip code income quartile					
Lowest quartile	89460128	478674	5.4	2053	4.3
2nd quartile	78497949	219619	2.8	801	3.6
3rd quartile	71474969	163233	2.3	836	5.1
Highest quartile	61340502	100769	1.6	703	7.0
Missing	6936433	25259	3.6	48	1.9
Primary Payer					
Medicare	141357438	315777	2.2	1736	5.5
Medicaid	50563783	428967	8.5	1725	4.0
Private Insurance	88933878	170459	1.9	671	3.9
Self-Pay	26247689	70526	2.7	304	4.3
Missing	607194	1825	3.0	—	—
Hospital Characteristics					
Hospital Region					
Northeast	33888883	46282	1.4	1226	6.1
Midwest	107572349	234180	2.2	1014	5.4
South	164884575	701680	4.3	1820	3.6

West	1364173	5411	4.0	382	4.4
Hospital Bed Size					
Small	46455596	114366	2.5	331	2.9
Medium	81563430	258481	3.2	998	3.9
Large	178326782	609296	3.4	3108	5.1
Missing	1364173	5411	4.0	—	—
Hospital Location and Teaching Status					
Rural	33888883	46282	1.4	96	2.1
Urban non-teaching	107572349	234180	2.2	749	3.2
Urban teaching	164884575	701680	4.3	3591	5.1
Missing	1364173	5411	4.0	—	—

SCD-Sickle Cell Disease

NH-Non-Hispanic

DAMA-Discharged Against Medical Advice

Prevalence is the rate of the outcome (SCD or palliative care use) among each patient characteristics

'—' represents cell values <10, which have been suppressed to preserve patient confidentiality, as per HCUP guidelines.

Table 2: Factors associated with palliative care use in SCD patients – overall and among those who died in-hospital


	Palliative care use in SCD hospitalizations	Palliative care use among SCD patients who died in-hospital
	OR(95% CI)	OR(95% CI)
Age Group		
18-39 years	reference	reference
40-59 years	0.98(0.81-1.18)	1.81(1.19-2.75)*
60-79 years	0.95(0.70-1.30)	1.13(0.60-2.12)
80+ years	2.34(1.41-3.88)*	2.29(0.79-6.64)
Race/Ethnicity		
NH-White	reference	reference
NH-Black	0.67(0.45-0.99)*	0.33(0.16-0.68)*
Hispanic	0.47(0.26-0.84)*	0.28(0.09-0.91)*
Others	0.83(0.49-1.39)	0.41(0.12-1.42)
Sex		
Male	reference	reference
Female	0.40(0.21-0.76)*	1.45(1.00-2.11)
Discharge Status		
Routine	reference	reference
Transfer	3.71(2.73-5.03)*	
Died	39.26(30.83-49.98)*	—
DAMA	0.48(0.28-0.84)*	—
Other	4.14(3.20-5.35)*	—
Zip code income quartile		
Lowest quartile	reference	reference
2nd quartile	0.89(0.71-1.11)	0.69(0.42-1.14)
3rd quartile	1.24(0.85-1.80)	0.48(0.25-0.91)*
Highest quartile	1.58(1.02-2.45)*	1.46(0.79-2.71)
Primary Payer		
Medicare	reference	reference
Medicaid	0.40(0.21-0.78)*	0.72(0.21-2.48)
Private Insurance	1.30(1.02-1.65)*	1.03(0.59-1.79)
Self-Pay	1.22(0.93-1.59)	1.12(0.64-1.99)
Hospital Characteristics		
Hospital Region		
Northeast	reference	reference
Midwest	1.00(0.57-1.75)	1.18(0.57-2.46)
South	0.69(0.42-1.11)	1.47(0.78-2.78)
West	0.72(0.40-1.31)	1.63(0.77-3.41)
Hospital Bed Size		
Small	reference	reference
Medium	1.47(1.02-2.12)*	1.18(0.57-2.44)
Large	1.91(1.30-2.82)*	1.52(0.78-2.96)
Hospital Location and Teaching Status		
Urban teaching	reference	reference
Rural	0.47(0.28-0.79)*	0.75(0.33-1.73)
Urban non-teaching	0.61(0.47-0.80)*	0.63(0.40-0.99)

1
2
3 SCD-Sickle Cell Disease
4 NH-Non-Hispanic
5 DAMA-Discharged Against Medical Advice
6 OR- odds ratio, CI- confidence interval
7 '—' represents the absence of variable in the model
8
9

10 **Figure legend/caption**

11 Figure 1: Temporal trends in the rates of palliative care use. Average annual percentage change
12 (AAPC) represents the overall change in rates of palliative care use during the study period
13 2008-2017. '*' represents statistically significant findings ($p < 0.05$). Rate of inpatient palliative
14 care service use increased at average of 9.2% per year (95% CI, 5.6-12.9) for all SCD-related
15 hospitalizations and 10.7% (95% CI, 3.4-18.5) for terminal hospitalizations.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5,6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7,8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7,8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7,8
Bias	9	Describe any efforts to address potential sources of bias	Not applicable
Study size	10	Explain how the study size was arrived at	Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Not applicable
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8,9
		(b) Describe any methods used to examine subgroups and interactions	Not applicable
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	7
		(e) Describe any sensitivity analyses	Not applicable
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	Not applicable

Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	22, 23
Outcome data	15*	Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11,12
		(b) Report category boundaries when continuous variables were categorized	Not applicable
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not applicable
Discussion			
Key results	18	Summarise key results with reference to study objectives	13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15,16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13,14,15
Generalisability	21	Discuss the generalisability (external validity) of the study results	16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057361.R3
Article Type:	Original research
Date Submitted by the Author:	12-Jul-2022
Complete List of Authors:	Nwogu-Onyemkpa, Eberechi; Baylor College of Medicine, Department of Medicine, Center of Excellence in Health Equity, Training and Research; Baylor College of Medicine, Section of Geriatrics and Palliative Medicine Dongarwar, Deepa; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Salihu, HM; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Akpati, Lois; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Marroquin, Maricarmen; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Abadom, Megan; Baylor College of Medicine, Center of Excellence in Health Equity, Training and Research Naik, Aanand; UTHealth School of Public Health, Management, Policy and Community Health; Michael E DeBakey VA Medical Center, Houston Center for Innovations in Quality, Effectiveness, and Safety
Primary Subject Heading:	Palliative care
Secondary Subject Heading:	Haematology (incl blood transfusion)
Keywords:	Adult palliative care < PALLIATIVE CARE, HAEMATOLOGY, Anaemia < HAEMATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

Title: Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

Eberechi Nwogu-Onyemkpa, MD^{1,2}, Deepa Dongarwar, MS¹, Hamisu M. Salihu, MD, PhD¹, Lois Akpati, BS¹, Maricarmen Marroquin, BS¹, Megan Abadom, BS¹, Aanand D. Naik, MD^{3,4}

Affiliations: ¹Baylor College of Medicine Center of Excellence in Health Equity, Training and Research, Houston, Texas

²Department of Medicine, Section of Geriatrics and Palliative Medicine, Baylor College of Medicine, Houston, Texas

³UTHealth Consortium on Aging; and Department of Management, Policy and Community Health, UT School of Public Health, Houston, Texas

⁴Houston Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas

28 Word count: 3,551

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Corresponding Author:

Eberechi Nwogu-Onyemkpa

eberechi.nwogu-onyemkpa@bcm.edu

6501 Fannin St. NC 100, Houston, Texas 77030

1
2
3
4
5
6
7 **Abstract:**
8
9

10 **Objective:** Sickle cell disease (SCD) is a highly morbid condition notable for recurrent
11 hospitalizations due to vaso-occlusive crises and complications of end organ damage. Little is
12 known about the use of inpatient palliative care services in adult patients with SCD. This study
13 aims to evaluate inpatient palliative care use during SCD related hospitalizations overall and
14 during terminal hospitalizations. We hypothesize that use of palliative care is low in SCD
15 hospitalizations.
16
17
18
19
20
21
22
23

24
25 **Design:** A retrospective cross-sectional study utilizing data from the National Inpatient Sample
26 (NIS) from 2008-2017 was conducted.
27
28
29

30
31 **Setting:** US hospitals from 47 states and the District of Columbia.
32
33

34 **Participants:** Patients >18 years old hospitalized with a primary or secondary ICD-9-CM or
35 ICD-10-CM diagnosis of SCD were included.
36
37
38
39

40 **Primary and secondary outcome measures:** Palliative care service use (documented by ICD-9-
41 CM and ICD-10-CM diagnosis codes V66.7 and Z51.5).
42
43
44

45 **Results:** 987,555 SCD-related hospitalizations were identified, of which 4442 (0.45%) received
46 palliative care service. Palliative care service use increased at a rate of 9.2% per year (CI, 5.6-
47 12.9). NH-Black and Hispanic patients were 33% and 53% less likely to have palliative care
48 services compared to NH-White patients (OR 0.67; CI 0.45-0.99 and OR 0.47; CI, 0.26-0.84).
49
50
51
52
53
54
55
56
57
58
59
60
Female patients (OR 0.40; CI, 0.21-0.76), Medicaid use (OR 0.40; CI, 0.21-0.78), rural (OR

1
2
3 0.47; CI 0.28-0.79) and urban non-teaching hospitals (OR 0.61; CI 0.47-0.80) each had a lower
4
5 likelihood of palliative care services use.
6
7

8
9 **Conclusion:** Use of palliative care during SCD-related hospitalizations is increasing but remains
10
11 low. Disparities associated with race and gender exist for use of palliative care services during
12
13 SCD related hospitalization. Further studies are needed to guide evidence-based palliative care
14
15 interventions for more comprehensive and equitable care of adult patients with SCD.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- Our study is the first of its kind to investigate palliative care use among SCD patients using a national database.
- ICD-9-CM and ICD-10-CM codes for palliative care are not specific to palliative care provided by a palliative care specialist as these codes also encompass patients who are in comfort care status.
- Our study investigated inpatient palliative care use and hence, our findings cannot be extrapolated to outpatient setting where patients with SCD patient receive most of their care.

Introduction:

Sickle cell disease (SCD) is a group of inherited red blood cell disorders in which abnormality in Hemoglobin (Hb) beta gene results in abnormal shape and sickling of red blood cells under stress. Physiologic manifestations of the illness arise from end organ ischemia, including acute pain from vaso-occlusive crises, cerebrovascular accident, acute chest syndrome, pulmonary hypertension, heart failure, renal failure, severe anemia, and recurrent infections.¹ Approximately 100,000 Americans predominantly of African (90%), Middle Eastern, and Mediterranean descent are affected by SCD.² Historically, SCD was a childhood disease – life expectancy for those with the disease was 20 years in 1970. Currently, life expectancy with SCD extends into adulthood (42-48 years) but remains significantly lower than the general population, especially for sickle cell anemia—the most severe form of SCD.³ As an increasing number of people with SCD survive into adulthood, there is a rising need for effective transitions to adult medicine involving multidisciplinary care teams.⁴

SCD is a highly morbid condition. Recurrent hospitalization is common in SCD due to vaso-occlusive crises and complications of end organ damage.^{5 6} During their last year of life, people with SCD were hospitalized for an average of forty-two days over five admissions.⁷ Hospital admissions and ED visits increase sharply a month before death and most patients with SCD die in the hospital (63%) or emergency department (15%).⁷ Patients with SCD experience increased rates of depression and anxiety,^{8 9 10} chronic pain,¹¹ and decreased health-related quality of life.¹² Increased healthcare use¹³ and symptom burden are salient opportunities for palliative care intervention in this patient population. Palliative care provides holistic care for patients with serious chronic illnesses using a multidisciplinary team approach.¹⁴ Palliative care has been

1
2
3 shown to increase patient's quality of life and decrease health care costs^{15 16} but the impact of
4
5 palliative care on SCD is not well characterized.¹⁷
6
7

8 Furthermore, little is known about the use of *inpatient* palliative care services in adult patients
9
10 with SCD. To address this gap, we used national data to evaluate inpatient palliative care use
11
12 during SCD related hospitalizations overall and during terminal hospitalizations (hospitalizations
13
14 that resulted in patients' death in-hospital regardless of cause of death). We identified patient and
15
16 hospital characteristics associated with use of hospital-based palliative care services in SCD. We
17
18 hypothesize that use of palliative care is low in SCD hospitalizations.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods:

Data Source

Data from the 2008 to 2017 National Inpatient Sample (NIS), the largest all-payer, nationally representative inpatient database in the United States (US) was used. The NIS is part of a group of databases developed by the Healthcare Utilization Project (HCUP) and sponsored by the Agency for Healthcare Research and Quality (AHRQ).¹⁸ This public database contains longitudinal data from a stratified sample of all discharges from US hospitals from 47 states and the District of Columbia, excluding rehabilitation and long-term acute care hospitals, thereby estimating about a 20% sample of all hospital discharges. When weighted, each year, NIS contains data from about 35 million hospitalizations.

Study Population and Variables

The analysis was restricted to hospitalizations in adults aged 18 years and above. Diagnoses and procedures are coded using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes till the 3rd quarter of 2015, after which HCUP transitioned to ICD-10-CM format. To identify the hospitalizations of interest, we first scanned the diagnosis codes (the principal diagnosis and up to 29 secondary diagnoses) in each patient's discharge record for an indication of SCD (ICD-9-CM - 282.41, 282.42, 282.61, 282.62, 282.63, 282.64, 282.60, 282.68, 282.69; ICD-10-CM - D57.4x, D57.0x, D57.2x, D57.1x, D57.8x). The study's primary outcome was palliative care use which was identified using ICD-9-CM diagnosis code V66.7 and ICD-10-CM diagnosis code Z51.5. The ICD-9-CM and ICD-10-CM palliative care codes capture hospital encounters by a palliative care specialist or service, patients admitted

1
2
3 for palliative care, and patients on comfort measures only status. There were no changes in the
4
5 criteria for palliative care code with the transition from ICD-9-CM to ICD-10-CM. Covariates
6
7 included in the study were socio-demographics for the patient which consisted of patients' age,
8
9 race/ethnicity – categorized as Non-Hispanic (NH)-White, NH-Black, Hispanic and NH-Others,
10
11 sex, insurance type – Medicare, Medicaid, private insurance, self-pay and others, median
12
13 household income based on zipcodes; and hospital characteristics such as hospital location,
14
15 hospital type (urban vs. rural and teaching vs. non-teaching), and hospital bed size.
16
17
18
19

20 Statistical Analysis

21
22
23
24 Since the NIS data was de-identified and publicly available, the study was approved as exempt
25
26 by the Institutional Review Board (IRB) of Baylor College of Medicine. All statistical tests were
27
28 two-tailed with the type-I error of 5% and were conducted using R version 3.5.1 (University of
29
30 Auckland, Auckland, New Zealand) and R Studio Version 1.1.423 (Boston, MA) and Joinpoint
31
32 Regression Program, version 4.7.0.0 (National Cancer Institute).
33
34
35

36
37 Temporal trends analyses were performed using Joinpoint regression technique, which enables
38
39 examination of the trend of an outcome (in this case, palliative care use) over the study period.¹⁹
40

41 The results are represented in the form of average annual percentage change (AAPC) and its
42
43 95% confidence interval (CI). We scrutinized the temporal trends in the rates of palliative care
44
45 use among SCD patients overall, and among those who died in-hospital. Next, we examined the
46
47 socio-demographic and hospitalization characteristics of patients with SCD and those with SCD
48
49 who received palliative care during their hospitalization. Prevalence rates of SCD and palliative
50
51 care use among SCD hospitalizations were calculated, stratified by patients' race/ethnicity.
52
53

54
55 Furthermore, after excluding records with missing values in model variables, we conducted
56
57
58
59

1
2
3 adjusted survey logistic regression models to examine the patient socio-demographic and
4
5 hospitalization characteristics (exposure variables) associated with palliative care use (outcome
6
7 variable) among all SCD hospitalizations and among those which resulted in patients' death in-
8
9 hospital. All the patient demographic and hospital characteristics were loaded into the
10
11 association models to obtain adjusted odds ratio and 95% confidence intervals.
12
13
14
15

16 **Patient and public involvement**

17
18 Patients were not involved in this retrospective analysis of an anonymized national inpatient
19
20 database.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results:***Trends in the rate of palliative care use in SCD-related hospitalizations***

During the study period of 1 January 2008 to 31 December 2017, the NIS contained 987,555 SCD-related hospitalizations of which 6,327 (0.64%) were terminal admissions. There were 4442 (0.45%) SCD-related hospitalizations that received palliative care service. Figure 1 shows temporal trends in palliative care use. The rate of inpatient palliative care service use increased at an average of 9.2% per year (95% CI, 5.6-12.9) for all SCD-related hospitalizations – from 2.86 per 1000 hospitalizations in 2008 to 6.32 per 1000 hospitalizations in 2017; and an average of 10.7% (95% CI, 3.4-18.5) for terminal hospitalizations – 6.34 per 1000 hospitalizations in 2008 to 15.82 per 1000 hospitalizations in 2017.

Patient characteristics – SCD hospitalizations with palliative care use

Table 1 shows patient characteristics for SCD related hospitalizations and patients who received palliative care services. The prevalence of SCD-related hospitalization was highest among the 18-39 age group (9.7 per 1000 SCD hospitalizations) and decreased with increasing age. Conversely, the prevalence of inpatient palliative care use was highest in the oldest age group (34.8 per 1000 SCD hospitalization) and lowest in the 18-39 age group (3.8 per 1000 SCD hospitalizations). The prevalence of SCD-related hospitalization was highest among NH-Blacks (20.7 per 1000 SCD hospitalizations) and lowest in NH-Whites (0.1 per 1000 SCD hospitalizations) while the prevalence of inpatient palliative care services was highest in NH-Whites (12.6 per 1000 SCD hospitalizations) and lowest in Hispanics (3.6 per 1000 SCD hospitalizations).

Regional and hospital characteristics – SCD hospitalizations with palliative care use

1
2
3 SCD hospitalization was lowest in the Northeast (1.4 per 1000 SCD hospitalizations) but the
4 prevalence of inpatient palliative care service was highest in this region (6.1 per 1000 SCD
5 hospitalizations). Conversely the South region had the highest prevalence of SCD hospitalization
6 (4.3 per 1000 SCD hospitalizations) but the lowest use of inpatient palliative care services (3.6
7 per 1000 SCD hospitalizations). Large and urban teaching hospitals had the highest prevalence
8 of SCD hospitalization (3.4 and 4.3 per 1000 hospitalizations, respectively) and highest level of
9 inpatient palliative care service use (5.1 and 5.1 per 1000 SCD hospitalizations, respectively).

20 ***Factors associated with inpatient palliative care use in SCD***

21
22 Table 2 shows factors associated with inpatient palliative care use in SCD hospitalizations.
23
24 During terminal hospitalizations patients between 40-59 years were more likely to receive
25 palliative care services than patients 18-39 years old (odds ratio [OR], 1.81, 95% confidence
26 interval [CI], 1.19-2.75). NH-Black and Hispanic patients were less likely to receive inpatient
27 palliative care services compared to NH-White (OR, 0.67; 95% CI, 0.45-0.99 and OR, 0.47; 95%
28 CI, 0.26-0.84, respectively). Likewise, during terminal admissions use of palliative care services
29 was less likely among NH-Black and Hispanic patients, respectively when compared to NH-
30 White (OR, 0.33; 95% CI, 0.16-0.68 and OR, 0.28; 95% CI, 0.09-0.91, respectively). Female
31 patients were less likely to receive palliative care services than male patients (OR, 0.40; 95% CI,
32 0.21-0.76). Compared to routine discharges, hospitalizations resulting in death and transfer to
33 another health care facility were associated with increased odds of use of inpatient palliative care
34 services (OR, 39.36; 95% CI, 30.83-49.98, and OR, 3.71; 95% CI, 2.73-5.03, respectively) while
35 discharge against medical advice (DAMA) was associated with decreased odds of use of
36 inpatient palliative care services (OR, 0.48; 95% CI 0.28-0.84).

1
2
3 Patients living in zip codes in the highest income quartile were more likely to receive inpatient
4 palliative care services (OR, 1.58; 95% CI 1.02-2.45) than those in the lowest quartile.

5
6
7 Compared to Medicare patients, those with Medicaid had lesser odds (OR, 0.40; 95% CI, 0.21-
8 0.78), while patients with private insurance had higher odds (OR, 1.30; 95% CI, 0.93-1.59) of
9 receiving palliative care services. During terminal admissions, there were no significant
10 differences in palliative care use across different payors.
11
12
13
14
15
16
17
18
19

20 Patients admitted to medium or large hospitals were more likely (OR, 1.47; 95% CI, 1.02-2.12
21 and OR, 1.91; 95% CI, 1.30-2.82, respectively) to receive palliative care services than patients in
22 small hospitals while patients admitted to rural or urban non-teaching hospitals were less likely
23 to receive palliative care services than those in urban teaching hospitals (OR, 0.47; 95% CI 0.28-
24 0.79 and OR, 0.61; 95% CI 0.47-0.80, respectively).
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion:

In this study of national trends, we found overall low use of palliative care services during SCD-related hospitalizations. Palliative care use was more likely among patients who were NH-White male, in the highest income quartile, with private insurance, and who received care in large or urban academic hospitals. NH-Black and Hispanic patients were less likely to receive palliative care services especially during terminal hospitalizations.

While early palliative care has gained acceptance in cancer care,²⁰ its adoption in other serious life limiting conditions such as congestive heart failure, chronic kidney disease, and SCD lags. SCD has traditionally been viewed as a childhood disease as most patients did not survive to adulthood in the past. Currently, most patients with SCD survive to adulthood.³ Furthermore, some patients with SCD experience complications and end organ damage from their disease resulting in a shortened life expectancy than the general population. Our study found a higher prevalence of palliative care service use in terminal admissions when compared to admissions with routine discharge or transfer to another level of care. This highlights an opportunity for palliative care involvement earlier in the disease course in SCD, facilitating more holistic care of patients. Earlier initiation of palliative care grants patients psychosocial support and symptom management from an interdisciplinary team,²¹ as well as honest discussions regarding goals of care and patient's preference for end of life.

Our study showed most SCD-related hospitalizations and palliative care service use were in the NH-Black group. However, further analysis accounting for covariates revealed that NH-Black patients were significantly less likely to receive palliative care during hospitalization compared to NH-white patients. Notably, race/ethnicity was the only factor associated with palliative care

1
2
3 use in both SCD and terminal hospitalizations. Other studies have shown racial disparities in the
4 use of palliative care services in other chronic diseases.^{22,23} Furthermore, studies have shown that
5 black patients are less likely to use hospice services and more likely to receive intensive life-
6 sustaining procedures at end of life compared to white patients.²⁴ Factors identified to drive this
7 racial disparity in hospice use include knowledge deficits,²⁵ mistrust of the health care system,²⁶
8 miscommunication and misunderstanding of treatment options,²⁷ and preference for more
9 aggressive care.²⁸ Similar studies are lacking to elucidate factors implicated in the racial
10 difference in non-hospice palliative care use across all life limiting diseases.²⁹ Palliative care has
11 a strong perceived association with hospice with many patients and families unable to
12 differentiate between the two. Therefore, the factors identified above relating to hospice use are
13 likely to also play a role in racial differences observed in palliative care use in patients with
14 chronic conditions such as SCD. Further studies are needed to investigate patient and system
15 factors associated with racial differences in palliative care use in SCD.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 Gender differences in the use of inpatient palliative care services were found. Although male and
34 female patients had a similar prevalence of SCD-related hospitalization, female patients were
35 60% less likely to receive palliative care services. This finding is contrary to that of other studies
36 which show that women are more receptive to palliative care than men.³⁰ Pain is the most
37 prominent feature of SCD and hence it is plausible that inpatient palliative care services in SCD
38 hospitalizations primarily involve pain management. Studies have shown that although most
39 chronic pain conditions are more prevalent in women than men, and women report greater pain
40 than men after invasive procedures, women receive less analgesia and are more likely to have
41 their pain attributed to psychological causes.³¹ It is possible that palliative care consultants are
42 more frequently involved for specialist level pain management for male than female patients
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 accounting for the gender difference observed in our study. This finding requires further
4 investigation as the study by McClish et al. demonstrates that men and women with SCD report
5 similar pain experiences.³²
6
7

8
9
10 We also found socioeconomic differences in the use of palliative care in SCD similar to other
11 diseases.^{23,33,34} Patients with zip codes in the highest income quartile and those with private
12 insurance were more likely to receive palliative care, while patients with Medicaid were less
13 likely to receive palliative care services. Insurance dictates patient's access to specialty care with
14 patients on Medicaid reporting more challenge than those with private insurance accessing
15 certain specialty care particularly in the outpatient setting.^{35,36}
16
17
18
19
20
21
22
23

24 Regional differences were detected in our study. The South region had the highest number of
25 SCD hospitalizations but the lowest prevalence of palliative care use. This finding is notable as
26 two of the three states (Florida, Texas, and New York) with the highest population of SCD
27 patients are in the South. Hospital characteristics were also predictive of palliative care use with
28 medium, large and urban teaching hospitals associated with greater use of palliative care in SCD
29 similar to findings from other studies.^{33 22 34} While many sickle cell patients use larger, urban
30 hospitals for their care,³⁷ this study highlights the need for improvement in access to palliative
31 care services across all settings in the US, particularly in small and rural hospitals.
32
33
34
35
36
37
38
39
40
41
42

43 To our knowledge, our study is the first of its kind to investigate palliative care use among SCD
44 patients using a national data base. Limitations exist in our study one of which is the validity of
45 the ICD-9 and ICD-10 codes for identification of palliative care consultations. Investigators have
46 sought to validate these codes however these studies utilize data from a single institution³⁸ or
47 from the VA system.³⁹ Furthermore, the ICD-9 and ICD-10 codes for palliative care are not
48 specific to palliative care provided by a palliative care specialist as these codes also encompass
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 patients who are in comfort care status.⁴⁰ Not all patients in comfort care are managed by a
4
5 palliative care specialist and as such it is difficult to delineate which hospitalizations were indeed
6
7 associated with the involvement of a palliative care specialist. In addition, our dataset does not
8
9 allow us to elucidate the nature of palliative care interventions provided during admissions hence
10
11 it is unclear if these interventions were for symptom management, goals of care discussion,
12
13 counseling and support, or transition to comfort care. Given utilization of aggregate data in
14
15 which a hospitalization is considered a single event, we are unable to identify the number of
16
17 patients who benefited from palliative care services as multiple admissions could be associated
18
19 with one patient. As such, we suspect that our study overestimates the prevalence of palliative
20
21 care use in SCD. Lastly, our study investigated inpatient palliative care use and hence, our
22
23 findings cannot be extrapolated to outpatient settings where patients with SCD patient receive
24
25 most of their care.
26
27
28
29

30
31 SCD related morbidity and mortality have a significant impact on patient self-reported quality of
32
33 life outcomes and healthcare utilization and cost. Early palliative care might guide patients'
34
35 treatment decisions and mitigate initiation of interventions that are not in line with a patients'
36
37 wishes at the end of life. Early palliative care also has the potential to improve symptom
38
39 management and consequently improve quality of life for individuals with SCD. Studies
40
41 exploring barriers and facilitators to early palliative care at the provider (SCD providers,
42
43 palliative care specialists), patient, and system levels do not exist and are needed for future
44
45 recommendation for PC interventions in this population. Racial disparity in the use of palliative
46
47 care by SCD patients should be investigated with studies assessing knowledge of palliative care
48
49 and barriers to palliative care use by SCD patients. Furthermore, studies addressing system
50
51
52
53
54
55
56
57
58
59
60

1
2
3 barriers to palliative care use among minority patients are needed as the implication spans across
4
5 other life limiting illnesses.
6
7

8 **Contributorship:**

9
10
11 Eberechi Nwogu-Onyemkpa was involved in the conception of the study, interpretation of data,
12
13 drafting, and revision of the manuscript.
14
15

16
17 Deepa Dongarwar was involved in the conception of the study, analysis of the data, drafting, and
18
19 revision of the manuscript.
20
21

22
23 Hamisu Salihu was involved in the conception of the study and revision of the manuscript.
24

25
26 Chioma Akpati was involved in the interpretation of data and drafting of the manuscript.
27

28
29 Maricarmen Marroquin was involved in the interpretation of data, drafting and revision of the
30
31 manuscript.
32

33
34 Megan Abadom was involved in the interpretation of data and drafting of the manuscript.
35

36
37 Aanand D. Naik was involved in the conception of the study and revision of the manuscript.
38
39

40 **Funding/Support:** Research funding support was provided by the US Department of Health and
41
42 Human Services and Health Resources and Services Administration for Baylor College of
43
44 Medicine Center of Excellence in Health Equity, Training, and Research (Grant No:
45
46 D34HP31024). Additional support is provided to Dr. Naik from the Houston VA HSR&D Center
47
48 for Innovations in Quality, Effectiveness, and Safety (CIN 13-413).
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Competing of Interests:** Authors *without* conflicts of interest, including relevant financial
4 interests, activities, relationships, and affiliations.
5
6

7
8 **Ethics Approval:** This study was approved as exempt by the Institutional Review Board (IRB)
9 of Baylor College of Medicine.
10
11

12
13 **Data Sharing:** All data relevant to the study are included in the article or uploaded as
14 supplementary information. We used data from the 2008 to 2017 National Inpatient Sample
15 (NIS) which is provided by the Healthcare Utilization Project (HCUP) and sponsored by the
16 Agency for Healthcare Research and Quality (AHRQ). Data can be accessed through the HCUP
17 website.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. *N Engl J Med*. Jul 20 2017;377(3):305. doi:10.1056/NEJMc1706325
2. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. *Am J Hematol*. Jan 2010;85(1):77-8. doi:10.1002/ajh.21570
3. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. *N Engl J Med*. Jun 9 1994;330(23):1639-44. doi:10.1056/NEJM199406093302303
4. Saulsberry AC, Porter JS, Hankins JS. A program of transition to adult care for sickle cell disease. *Hematology Am Soc Hematol Educ Program*. Dec 6 2019;2019(1):496-504. doi:10.1182/hematology.2019000054
5. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. *N Engl J Med*. May 18 1995;332(20):1317-22. doi:10.1056/NEJM199505183322001
6. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. *JAMA*. Apr 2 2003;289(13):1645-51. doi:10.1001/jama.289.13.1645
7. Johnston EE, Adesina OO, Alvarez E, et al. Acute Care Utilization at End of Life in Sickle Cell Disease: Highlighting the Need for a Palliative Approach. *J Palliat Med*. Jan 2020;23(1):24-32. doi:10.1089/jpm.2018.0649
8. Levenson JL, McClish DK, Dahman BA, et al. Depression and anxiety in adults with sickle cell disease: the PiSCES project. *Psychosom Med*. Feb 2008;70(2):192-6. doi:10.1097/PSY.0b013e31815ff5c5
9. Adam SS, Flahiff CM, Kamble S, Telen MJ, Reed SD, De Castro LM. Depression, quality of life, and medical resource utilization in sickle cell disease. *Blood Adv*. Oct 24 2017;1(23):1983-1992. doi:10.1182/bloodadvances.2017006940
10. Laurence B, George D, Woods D. Association between elevated depressive symptoms and clinical disease severity in African-American adults with sickle cell disease. *J Natl Med Assoc*. Mar 2006;98(3):365-9.
11. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. *Blood Adv*. Jun 23 2020;4(12):2656-2701. doi:10.1182/bloodadvances.2020001851
12. Lee S, Vania DK, Bhor M, Revicki D, Abogunrin S, Sarri G. Patient-Reported Outcomes and Economic Burden of Adults with Sickle Cell Disease in the United States: A Systematic Review. *Int J Gen Med*. 2020;13:361-377. doi:10.2147/IJGM.S257340
13. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. *Am J Hematol*. Jun 2009;84(6):323-7. doi:10.1002/ajh.21408
14. Sepulveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: the World Health Organization's global perspective. *J Pain Symptom Manage*. Aug 2002;24(2):91-6. doi:10.1016/s0885-3924(02)00440-2
15. Casarett D, Pickard A, Bailey FA, et al. Do palliative consultations improve patient outcomes? *J Am Geriatr Soc*. Apr 2008;56(4):593-9. doi:10.1111/j.1532-5415.2007.01610.x
16. Gade G, Venohr I, Conner D, et al. Impact of an inpatient palliative care team: a randomized control trial. *J Palliat Med*. Mar 2008;11(2):180-90. doi:10.1089/jpm.2007.0055
17. Ajayi TA, Edmonds KP, Thornberry K, Atayee RA. Palliative Care Teams as Advocates for Adults with Sickle Cell Disease. *J Palliat Med*. Feb 2016;19(2):195-201. doi:10.1089/jpm.2015.0268
18. NIS Database Documentation. Accessed June 1, 2021, <https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp>

19. National Cancer Institute. Joinpoint trend analysis software. Accessed June 1, 2021, <https://surveillance.cancer.gov/joinpoint/>
20. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med*. Aug 19 2010;363(8):733-42. doi:10.1056/NEJMoa1000678
21. Osunkwo I, Andemariam B, Minniti CP, et al. Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY). *Am J Hematol*. Apr 1 2021;96(4):404-417. doi:10.1002/ajh.26063
22. Wen Y, Jiang C, Koncicki HM, et al. Trends and Racial Disparities of Palliative Care Use among Hospitalized Patients with ESKD on Dialysis. *J Am Soc Nephrol*. Sep 2019;30(9):1687-1696. doi:10.1681/ASN.2018121256
23. Lee K, Gani F, Canner JK, Johnston FM. Racial Disparities in Utilization of Palliative Care Among Patients Admitted With Advanced Solid Organ Malignancies. *Am J Hosp Palliat Care*. May 6 2020;1049909120922779. doi:10.1177/1049909120922779
24. Ornstein KA, Roth DL, Huang J, et al. Evaluation of Racial Disparities in Hospice Use and End-of-Life Treatment Intensity in the REGARDS Cohort. *JAMA Netw Open*. Aug 3 2020;3(8):e2014639. doi:10.1001/jamanetworkopen.2020.14639
25. Johnson KS, Kuchibhatla M, Tulsy JA. Racial differences in self-reported exposure to information about hospice care. *J Palliat Med*. Oct 2009;12(10):921-7. doi:10.1089/jpm.2009.0066
26. Cort MA. Cultural mistrust and use of hospice care: challenges and remedies. *J Palliat Med*. Feb 2004;7(1):63-71. doi:10.1089/109662104322737269
27. Mack JW, Paulk ME, Viswanath K, Prigerson HG. Racial disparities in the outcomes of communication on medical care received near death. *Arch Intern Med*. Sep 27 2010;170(17):1533-40. doi:10.1001/archinternmed.2010.322
28. Barnato AE, Anthony DL, Skinner J, Gallagher PM, Fisher ES. Racial and ethnic differences in preferences for end-of-life treatment. *J Gen Intern Med*. Jun 2009;24(6):695-701. doi:10.1007/s11606-009-0952-6
29. Johnson KS. Racial and ethnic disparities in palliative care. *J Palliat Med*. Nov 2013;16(11):1329-34. doi:10.1089/jpm.2013.9468
30. Saeed F, Hoerger M, Norton SA, Guancial E, Epstein RM, Duberstein PR. Preference for Palliative Care in Cancer Patients: Are Men and Women Alike? *J Pain Symptom Manage*. Jul 2018;56(1):1-6 e1. doi:10.1016/j.jpainsymman.2018.03.014
31. Gott M, Morgan T, Williams L. Gender and palliative care: a call to arms. *Palliat Care Soc Pract*. 2020;14:2632352420957997. doi:10.1177/2632352420957997
32. McClish DK, Levenson JL, Penberthy LT, et al. Gender differences in pain and healthcare utilization for adult sickle cell patients: The PiSCES Project. *J Womens Health (Larchmt)*. Mar 2006;15(2):146-54. doi:10.1089/jwh.2006.15.146
33. Patel AA, Walling AM, Ricks-Oddie J, May FP, Saab S, Wenger N. Palliative Care and Health Care Utilization for Patients With End-Stage Liver Disease at the End of Life. *Clin Gastroenterol Hepatol*. Oct 2017;15(10):1612-1619 e4. doi:10.1016/j.cgh.2017.01.030
34. Yu KG, Shen JJ, Kim PC, et al. Trends of Hospital Palliative Care Utilization and Its Associated Factors Among Patients With Systemic Lupus Erythematosus in the United States From 2005 to 2014. *Am J Hosp Palliat Care*. Mar 2020;37(3):164-171. doi:10.1177/1049909119891999
35. Lee L, Smith-Whitley K, Banks S, Puckrein G. Reducing Health Care Disparities in Sickle Cell Disease: A Review. *Public Health Rep*. Nov/Dec 2019;134(6):599-607. doi:10.1177/0033354919881438
36. Timbie JW, Kranz AM, Mahmud A, Damberg CL. Specialty care access for Medicaid enrollees in expansion states. *Am J Manag Care*. Mar 1 2019;25(3):e83-e87.

- 1
2
3 37. Fingar KR, Owens PL, Reid LD, Mistry KB, Barrett ML. Characteristics of Inpatient Hospital Stays
4 Involving Sickle Cell Disease, 2000-2016: Statistical Brief #251. *Healthcare Cost and Utilization Project*
5 *(HCUP) Statistical Briefs*. 2006.
6
7 38. Hua M, Li G, Clancy C, Morrison RS, Wunsch H. Validation of the V66.7 Code for Palliative Care
8 Consultation in a Single Academic Medical Center. *J Palliat Med*. Apr 2017;20(4):372-377.
9 doi:10.1089/jpm.2016.0363
10
11 39. Feder SL, Redeker NS, Jeon S, et al. Validation of the ICD-9 Diagnostic Code for Palliative Care in
12 Patients Hospitalized With Heart Failure Within the Veterans Health Administration. *Am J Hosp Palliat*
13 *Care*. Jul 2018;35(7):959-965. doi:10.1177/1049909117747519
14
15 40. Stubbs JM, Assareh H, Achat HM, Greenaway S, Muruganatham P. Specialist Palliative Care
16 Activity at an Acute Care Tertiary Hospital and Its Representation in Administrative Data. *Am J Hosp*
17 *Palliat Care*. Mar 2021;38(3):216-222. doi:10.1177/1049909120939861
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Patient characteristics among SCD-related hospitalizations and among those with SCD who received palliative care during their hospitalization

	Total N=307709982	SCD-related hospitalizations N=987555	Prevalence of SCD-related hospitalizations (per 1000 hospitalizations)	SCD-related hospitalizations receiving palliative care N=4442	Prevalence of palliative care use (per 1000 SCD hospitalizations)
Age Group					
18-39 years	75567499	733837	9.7	2824	3.8
40-59 years	78526326	214939	2.7	1160	5.4
60-79 years	101611492	35362	0.3	339	9.6
80+ years	52004665	3417	0.1	119	34.8
Race/Ethnicity					
NH-White	192567014	16962	0.1	214	12.6
NH-Black	41490748	857006	20.7	3773	4.4
Hispanic	29897432	32676	1.1	116	3.6
Others	17422072	23026	1.3	157	6.8
Missing	26332714	57883	2.2	181	3.1
Sex					
Male	125745784	427285	3.4	1921	4.5
Female	181778482	559845	3.1	2521	4.5
Missing	185716	424	2.3	—	—
Discharge Status					
Routine	202797074	853218	4.2	2619	3.1
Transfer	55186460	37409	0.7	447	11.9
Died	6740712	6327	0.9	685	108.3
DAMA	3847845	44520	11.6	69	1.5
Other	38933666	45507	1.2	622	13.7
Missing	204225	573	2.8	—	—
Zip code income quartile					
Lowest quartile	89460128	478674	5.4	2053	4.3
2nd quartile	78497949	219619	2.8	801	3.6
3rd quartile	71474969	163233	2.3	836	5.1
Highest quartile	61340502	100769	1.6	703	7.0
Missing	6936433	25259	3.6	48	1.9
Primary Payer					
Medicare	141357438	315777	2.2	1736	5.5
Medicaid	50563783	428967	8.5	1725	4.0
Private Insurance	88933878	170459	1.9	671	3.9
Self-Pay	26247689	70526	2.7	304	4.3
Missing	607194	1825	3.0	—	—
Hospital Characteristics					
Hospital Region					
Northeast	33888883	46282	1.4	1226	6.1
Midwest	107572349	234180	2.2	1014	5.4
South	164884575	701680	4.3	1820	3.6

West	1364173	5411	4.0	382	4.4
Hospital Bed Size					
Small	46455596	114366	2.5	331	2.9
Medium	81563430	258481	3.2	998	3.9
Large	178326782	609296	3.4	3108	5.1
Missing	1364173	5411	4.0	—	—
Hospital Location and Teaching Status					
Rural	33888883	46282	1.4	96	2.1
Urban non-teaching	107572349	234180	2.2	749	3.2
Urban teaching	164884575	701680	4.3	3591	5.1
Missing	1364173	5411	4.0	—	—

SCD-Sickle Cell Disease

NH-Non-Hispanic

DAMA-Discharged Against Medical Advice

Prevalence is the rate of the outcome (SCD or palliative care use) among each patient characteristics

'—' represents cell values <10, which have been suppressed to preserve patient confidentiality, as per HCUP guidelines.

Table 2: Factors associated with palliative care use in SCD patients – overall and among those who died in-hospital

	Palliative care use in SCD hospitalizations	Palliative care use among SCD patients who died in-hospital
	OR(95% CI)	OR(95% CI)
Age Group		
18-39 years	reference	reference
40-59 years	0.98(0.81-1.18)	1.81(1.19-2.75)*
60-79 years	0.95(0.70-1.30)	1.13(0.60-2.12)
80+ years	2.34(1.41-3.88)*	2.29(0.79-6.64)
Race/Ethnicity		
NH-White	reference	reference
NH-Black	0.67(0.45-0.99)*	0.33(0.16-0.68)*
Hispanic	0.47(0.26-0.84)*	0.28(0.09-0.91)*
Others	0.83(0.49-1.39)	0.41(0.12-1.42)
Sex		
Male	reference	reference
Female	0.40(0.21-0.76)*	1.45(1.00-2.11)
Discharge Status		
Routine	reference	reference
Transfer	3.71(2.73-5.03)*	
Died	39.26(30.83-49.98)*	—
DAMA	0.48(0.28-0.84)*	—
Other	4.14(3.20-5.35)*	—
Zip code income quartile		
Lowest quartile	reference	reference
2nd quartile	0.89(0.71-1.11)	0.69(0.42-1.14)
3rd quartile	1.24(0.85-1.80)	0.48(0.25-0.91)*
Highest quartile	1.58(1.02-2.45)*	1.46(0.79-2.71)
Primary Payer		
Medicare	reference	reference
Medicaid	0.40(0.21-0.78)*	0.72(0.21-2.48)
Private Insurance	1.30(1.02-1.65)*	1.03(0.59-1.79)
Self-Pay	1.22(0.93-1.59)	1.12(0.64-1.99)
Hospital Characteristics		
Hospital Region		
Northeast	reference	reference
Midwest	1.00(0.57-1.75)	1.18(0.57-2.46)
South	0.69(0.42-1.11)	1.47(0.78-2.78)
West	0.72(0.40-1.31)	1.63(0.77-3.41)
Hospital Bed Size		
Small	reference	reference
Medium	1.47(1.02-2.12)*	1.18(0.57-2.44)
Large	1.91(1.30-2.82)*	1.52(0.78-2.96)
Hospital Location and Teaching Status		
Urban teaching	reference	reference
Rural	0.47(0.28-0.79)*	0.75(0.33-1.73)
Urban non-teaching	0.61(0.47-0.80)*	0.63(0.40-0.99)


1
2
3 SCD-Sickle Cell Disease
4 NH-Non-Hispanic
5 DAMA-Discharged Against Medical Advice
6 OR- odds ratio, CI- confidence interval
7 '—' represents the absence of variable in the model
8
9

10 **Figure legend/caption**

11 Figure 1: Temporal trends in the rates of palliative care use 2008-2017.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5,6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7,8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7,8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7,8
Bias	9	Describe any efforts to address potential sources of bias	Not applicable
Study size	10	Explain how the study size was arrived at	Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Not applicable
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8,9
		(b) Describe any methods used to examine subgroups and interactions	Not applicable
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	7
		(e) Describe any sensitivity analyses	Not applicable
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	Not applicable

Inpatient palliative care use by patients with sickle cell disease: a retrospective cross-sectional study

Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	22, 23
Outcome data	15*	Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11,12
		(b) Report category boundaries when continuous variables were categorized	Not applicable
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not applicable
Discussion			
Key results	18	Summarise key results with reference to study objectives	13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15,16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13,14,15
Generalisability	21	Discuss the generalisability (external validity) of the study results	16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.